Engineering Orthogonal Polypeptide GalNAc-Transferase and UDP-Sugar Pairs

Junwon Choi,¹ Lauren J. S. Wagner,¹ Suzanne B. P. E. Timmermans, Stacy A. Malaker, Benjamin Schumann, Melissa A. Gray, Marjoke F. Debets, Megumi Takashima, Jase Gehring, Carolyn R. Bertozzi*

*Corresponding author bertozzi@stanford.edu

¹These authors contributed equally to this work.

Supporting Information

Table of Contents

I.	Supporting Figures and Tables	S–2
	(Figures S1–S7; Tables S1 and S2)	
II.	General Information	S-14
III.	Glycosyltransferase Enzymatic Activity Assays	S-15
	(Figures S4, S5, S6, 3, 5A, and 5B)	
IV.	Glycosylation Reaction Kinetics	S–22
	(Table 1; Figure 5C)	
V.	UDP-Sugar Competition Experiment	S–27
	(Figure 4)	
VI.	Glycosylation of Natural Peptide Substrates by GalNAc-Ts	S-28
	(Figure 6)	
VII.	Preparation of GalNAc-Ts	S-44
	(Table S2; Figure S7)	
VIII.	Characterization of Chromophore-Labeled Peptides	S –46
	(Figure 2A)	
IX.	Preparation of UDP-Sugars	S-47
	(Figures 2B and 2C)	
X.	References	S-79
XI.	NMR Spectra	S-82

I. Supporting Figures and Tables




Figure S1. Alignment of GalNAc-T10 and GalNAc-T2 crystal structures. GalNAc-T10 (blue; co-crystallized with UDP and GalNAc, PDB ID: 2D71)¹ aligned with GalNAc-T2 (orange; co-crystallized with UDP-GalNAc, PDB ID: 4D0T).² The three-dimensional structure of the active site of the two enzymes is closely conserved. Labeled structures include bound UDP-GalNAc (sticks), UDP-GalNAc methyl group (Me), and Mn²⁺ (purple sphere). Side chains of potential gatekeeper residues (sticks) are labeled with GalNAc-T2 residue names; GalNAc-T10 residue names are listed parenthetically. GalNAc-T2 served as the reference structure.

	. 10 .	20 . 30	40	50	60	70	80	90 100	
hT8/1-637 hT18/1-607 hT9/1-603									
hT19/1-598 hT10/1-603									
hT17/1-584 hT7/1-657 hT5/1-940	MNRIPKEERCSCRVIA				FRVOPDOCKI	E Y S S I K EMK P P I	RCHCKCAWCKE	NVPKTFFSVIKVF	 VDI
hT11/1-608 hT20/1-443									
hT15/1-639 hT3/1-633									
hT6/1-622 hT4/1-578 hT12/1-581									
hT1/1-559 hT13/1-556									
hT2/1-571 hT14/1-552									
hT16/1-558									
hT8/1–637 hT18/1–607	110 , 120	130	140 1	16	170	180	190	200	210
hT18/1-607 hT9/1-603 hT19/1-598									
hT10/1-603 hT17/1-584									
hT7/1–657 hT5/1–940 hT11/1–608	DQ T Q R E R K MQ N A L G R G	K V V P L W H P A H L Q T L I	VTPNKQKTDGRGT	<pre>K P E A S S HQ G T P H</pre>	QTTAQGAPKT	SFIAAKGTQVVK	ISVHMGRVSLK	QEPRKSHSPSSDT	SKLAAERD
hT20/1-443 hT15/1-639									
hT3/1-633 hT6/1-622									
hT4/1-578 hT12/1-581 hT1/1-559									
hT13/1-556 hT2/1-571									
hT14/1-552 hT16/1-558									
hT8/1-637	220 230	240	250	260 . 27	0 , 280	290	300	310	320
hT18/1-607 hT9/1-603			MVC			TRKTKTLV	STCVIL-SGM	NIICLLYVGWVTN	IY I A SVYVR
hT19/1-598 hT10/1-603			MAS			L R R V K V L L	V L N L I	AVAGFVL-	F L A K C R
hT17/1-584 hT7/1-657 hT5/1-940	LNVTISLSTDRPKORS	OAVANERAHPASTA	VPKSGEAMALNKTK	TO SK EVNANKH		MR LK-	- IGFILRSLL- NETPLG-SLS	VVGSFLG	LV
hT11/1-608 hT20/1-443									
hT15/1-639 hT3/1-633 hT6/1-622			MLL			RKRYRHRPC	R LQ F L L – L L L – K R H Y H K – K F W	KLGCVLM	IMVAMLHP-
hT4/1-578 hT12/1-581									
hT1/1-559 hT13/1-556									
hT2/1-571 hT14/1-552 hT16/1-558									
hT8/1-637	330 340 LQNLFTGGLH GQEPSQELVI PIAVRSGDAFI	350 LELPLH	360 3 LNKRYGAV	70 380 KR-LSHLEVEL	390 QDL	400 KESMKLALI	410 RQQENV	420 – – N S T L K R A K D E V I	430 RPLLKAME
hT18/1-607 hT9/1-603 hT19/1-598	LQGR SQ ELVI P LAV R SG DAFI	- – – AP – – – – – – – – – – – – – – – –	VGT LG DT LK TT VGT LG DR EA T L HSASP TO DAVL	QR - LDHLENVI QR - LDHLEEVV KR - LSLLEDIV	K				
hT10/1-603 hT17/1-584		M R R K E K R - L L	Q A V A L V L	AALVLLPNVGL	WALYRERQ			- P D G T P G G S G A A V / R A G A G HO R I	AP – – AAGQ NPSISADH
hT7/1-657 hT5/1-940 hT11/1-608	V LWS S L T P R P I I T K E E E Q K J	DDP SPL SRMREDRDV ADP KEVSNSKTKT I F	N D P M P N R G G N G L A - P	P G E D R F K P V V P K V L G K S Q S	WPH KHISRNRSEMS	V E G V E V D L S S S S L A P H R V P L	ESIRRINKAKN SQTNH	EQEHHAGGDSQK	T A - - K A P S
hT20/1-443 hT15/1-639	P HHT L HQT V TA - QA S K I	RRNAIIQGLF	Y	GS-LTFGI	WTA	LLFIYLHHI	NHV S S	WQ K K SQ E P L S AW E D E G E E Y S	
hT3/1-633 hT6/1-622	MQREVSVQY – S – KEESI LHRDVSSREEA – TEKPV	UMERNMKNKNKN	L	D LM L E A V N D LM L E A M N	N I	K R	DAMP K DSMP K	MQ G A P V R Q N L Q R A P E A Q Q	
hT4/1-578 hT12/1-581 hT1/1-559	MAVRWIW		L	LVLLA	¥ F	VE LL LA GL(LDMFLLLY	V S T F H G S V L R F S F C N	A S A G A G R A R · A Q R G A G A G · K C D F K K F R G L - ·	
hT13/1-556 hT2/1-571		YC	K	V V L A T S L M M L L C F A F L	WVL	V D V F L L L Y G I A Y Y M Y S	F S E C N G G G S A	K C D D K K E R S L L A G G A G G G A G	
hT14/1-552 hT16/1-558		RR RLTRR RRKIRA	L	V L P V F G V L A I A I L T V A	W T	V - L L F FWV GT FYY LWQI	Г К R К – – – – – – L D N R A – – – – – – Н	E V P T G P E V Q T A A S S G G R G A Q	
hT8/1-637	440 450 T K V N E T K K H K T Q Q H I Q E A P A K P E A E A N Q L N G L A K P I G L V E C R Q L N G L S K S L G L I E C G S H S R Q K K G V H E L V Y Q T F P L G L G D D I M Q D V L T F K P	460	470 4	80 490 FROWG	, ⁵⁰⁰	510	520	530 DLFRKFGYNAYLSI	540 NOLPLNRT
hT18/1-607 hT9/1-603	Q H I – – Q E A P A K P E E A E A NQ L – – NG L A K P I G L V E G	EP F	T D S S L	F A HWG		Q E L S P E G R F A T L R D D - G C	RVAL 2EAE	K Q F Q Y Y G Y N A Y L S I G K Y E E Y G Y N A Q L S I	DR L P L DR P DR I S L DR S
hT19/1-598 hT10/1-603 hT17/1-584		- T F F L G D G Q K L K DW	HDKEAIRRDAQRVG	K G G L P N G E Q G R P		A T L S P A E E I	E K A K - Y P M T D A E R V D - Y P I T F F D H D D	G P H E K Y G Y N S Y L S I Q A Y R E NG F N I Y V S I S A Y R F NG F N I F V S I	EKISLDRS DKISLNRS NNIALERS
hT7/1-657 hT5/1-940	TEYNOSHIKALL	PEDSGTHOVLRI	- DVTL SPRDPKA	P GO F G R P		VVVP HGK EF	(EAE	RRWKEGNFNVYLSI	DLIPVDRA
hT11/1-608 hT20/1-443 hT15/1-639	G P H G P S P K K F Y P S P G K K V H Q P L E G L P								
hT3/1-633 hT6/1-622	- I DA- G ERP CLQ T LF S- I NQ S C LP - E LG- S R R L S D L AA EP GP P - P AG	GYYTAAELKPV- GFYTPAELKPF-	- L D R P P Q D S NA - W E R P P Q D S NA	P GA S G K A		- FKTTNLSVEEQF - FOKSKWTPLETO	(EKE) EKE	R G E A K H C F N A F A S I E G Y K K H C F N A F A S I	DRISLHRD
hT4/1-578 hT12/1-581	- E L G - S R R L S D L	Q K N T E D L S R P L - R T P R P G R R E P V -	– Y K K P – – – P A D S R A – M P R P – – – P V P A N A	L G E W G K A L G A R G E A		SKL-QLNEDEL VRL-QLQGEEL	(QQ E R LQ E	E L I E R Y A I N I Y L S I E S V R L HQ I N I Y L S I	DR I S L H R H DR I S L H R R
hT1/1-559 hT13/1-556 hT2/1-571									
hT14/1-552 hT16/1-558	RKE 	PS		QLREDRTIP	DADWDDLWDQ F LIVTGTPSKGF	F D E R R Y L N A K K W F F D E K A Y L S A K Q L F	QVGD (AGE	DPYKLYAFNQRES DPYRQHAFNQLESI	ER ISSNRA DKLSPDRP
	550 560	570	580 59	90 600		620	630	640	650
hT8/1-637 hT18/1-607 hT9/1-603	I – P D T R D Y R C L R K T – – Y L – P D L R P S G C R N L S – – F I – P D Y R P R K C R Q M S – – Y	PDSLPEVSIVFIFV	NEALSVLLRSIHSA	MERTPPHLLKE	IILVDDNSSNE	ELKEKLTEYVDK	VNSQKPGFIK	V V R H S K Q E G L I R S R	R V S GWR A A
hT19/1-598 hT10/1-603	I - P DY R P T K C K C K UK Y I - P D Y R P T K C K E L K Y L - P D I R HP N C N S K R Y	SKDLPQISIIFIFV	NEALSVILRSVHSA	VNHTPTHLLKE	IILVDDNSDEE	ELKVPLEEYVHK	R Y P G L V K	VRNQKREGLIRAR	RIEGWKVA
hT17/1-584 hT7/1-657	L – P D I R HANCK HKM – – Y V – ND L RQ E E CK YWH – – Y I – E D T R P A G C A E Q L – – V	LERLPNTSIIIPFH	NEGWTSLLRTIHSI	INRTPGSLIAE	IILVDDFSERE	HLKDKLEEYMAR	F-SKVR	IVRTKKREGLIRTR	RLLGASMA
hT5/1-940 hT11/1-608 hT20/1-443	I – EDTRPAGCAEQL – – V V – PDTRNAACKEKF – – Y V – PDTRSKMCLQKH – – Y	PPDLPAASVVICFY	NEAFSALLRTVHSV	IDRTPAHLLHE	IILVDDDSDFD	DLKGELDEYVQK	Y L P G K I K	VIRNTKREGLIRGR	RMIGAAHA
hT15/1-639 hT3/1-633	L – P EVR HP LCLQQH – – P LGP DT R P P EC I EQK FKR	QDSLPTASVILCFH CPPLPTTSVIIVFH	DEAWSTLLRTVHSI NEAWSTLLRTVHSV	L D T V P R A F L K E L Y S S P A I L L K E	IILVDDLSQQG IILVDDASVDE	Q L K S A L S E Y V A R Y L H D K L D E Y V K Q	1 L - EGVK 1 F - S I VK	L L R S N K R L G A I R A F I V R Q R E R K G L I T A F	RMLGATRA R L L GATVA
hT6/1-622 hT4/1-578	L G P D T R P P E C V D Q K F R R I – E D K R M Y E C K S Q K F N Y	CPPLATTSVIIVFH - RTLPTTSVIIAFY	N E A W S T L L R T V Y S V N E A W S T L L R T I H S V	LHTTPAILLKE LETSPAVLLKE	IILVDDASTEE IILVDDLSDRV	EHLKEKLEQYVKC YYLKTQLETYISN	l L - Q V V R I L - D R V R	V V R Q E E R K G L I T A F L I R T N K R E G L V R A F	R L L G A S V A R L I G A T F A
hT12/1-581 hT1/1-559 hT13/1-556	L – P V RWNP L C K E K K Y D Y L – P D V R L E G C K T K V – – Y L – P D V R L E G C K T K V – – Y	PDNLPTTSVVIVFH	NEAWSTLLRTVHSV	INRSPRHMIEE	IVLVDDASERD) F L K R P L E S Y V K K	. – – – L K – V P V H	VIRMEQRSGLIRAR	R L K G A A V S
hT2/1-571 hT14/1-552	I - P D T R H D Q C Q R K Q W I - P D T R H L R C T L L V Y	RVDLPATSVVITFH CTDLPPTSIIITFH	N E A R S A L L R T V V S V N E A R S T L L R T I R S V	LKKSPPHLIKE LNRTPTHLIRE	IILVDDYSNDP IILVDDFSNDP	' EDGA L L C ' DDCK Q L I	KI-EKVR KL-PKVK	V L R N D R R E G L M R S F C L R N N E R Q G L V R S F	R V R G A D A A R I R G A D I A
hT16/1-558	I - R D T R H Y S C P S V S Y	SSDLPATSVIITFH	NEARSTLLRTVKSV	LNRTPANLIQE	IILVDDFSSDP	EDCLLLT	RI-PKVK	CLRNDRREGLIRSE	VRGADVA

S-3

	660 670 680 690 700 710 720 730 740 750 760
hT8/1-637	- TADVVAILDAHIEVNYGWAEPILARIOEDRTVIVSPVFDNIRFDTFKLDKYELAVDGFNWELWCRYDALPOAWIDLHDVTAPVKSPSIMGI-LAANRHFLG
hT18/1-607	
hT9/1-603	- TAP VVG FFDAHVE FNT GWAEPALSR I REDRRRIVLPAIDNIKY ST FEVQQYA NAAHGY NWGLRCMY I I PPQDWLD RGDE SAPIRT PAMIGC SF VVD REY FG
hT19/1-598 hT10/1-603	- T GQ V T G F F D A H V E F T A GWA E P V L S R I Q E N R K R V I L P S I D N I K Q D N F E V Q R Y E N S A H G Y S W E L W C M Y I S P P K D W D A G D P S L P I R T P A M I G C S F V V N R K F F G
hT17/1-584	- I GDV I I FLDSHCEANVNWLPP LLDR I AKNRK I I VCPM I DVI DDI RY EI QAGDAMK GAFDWEMYYK I PI PP ELQKADP SDP EE SPYMAGGEFAVDKKWI W
hT7/1-657	- RGEVELTEDS INCENTING TO LEAD TALL AND TO LEAD TALL AND TO LEAD TALL AND TO LEAD TALL AND TALL A
hT5/1-940	T GDV LT F LD S HV ECNVGWL EP LLE R VY LSR K KVACP V I EV INDK DM SYMTYD NFORG I F VWP MN F GWRT I PP DV I AK NR I K ET DT I R CP VMAGG F S I DK SY F F
hT11/1-608	- LAPVVALE DARIVERVEGWAEFVLIK IK ENKKRIISPS IDNIK UNFELETP LAAUGVBEUKCKIKNPRAWWK LENSIAPIKSPALIGL-FIVDRUTUG - TAPVVAEFDARVEFNVGWAEFVLIK IK ENKKRIISPS IDNIK STEFUGVA
hT20/1-443	
hT15/1-639 hT3/1-633	- T G D V L V FMDA H C E C H P G W L E P L L S R I A G D R S R V V S P V I D V I D W K T F Q Y P S K D L Q R G V L D W L D F H W E P L P E H V R KA - L Q S P I S P I R S P V P G E V V A M D R H Y F Q
hT6/1-622	- T GDU LY FMDAHCECHP GWLEP LLSR I AC DR SRVVS PV I DV I DWKT TQYYP SK D LQ & GU LWKLD FHWEPL P EHVRKA - LQ SP I SP I R SPVYP GEVVAMDR HY FQ - T AE TLT FLDAHCECFY GWLEP LLAR I AE NYT AVV SPD I AS I DLNT FE FAKP SPY - GSNHNR GNFDWSLS FGWESLP DHEKQR - RKDETYP I KTP T FAGGLF SI SK EY FE - QAEVLT FLDAHCECFH GWLEP LLAR I AE DKT VV SPD I VT I DLNT FE FAKP VQR - GR VHSR GNFDWSLS FGWETLP PHEKQR - RKDETYP I KSPT FAGGLF SI PK SYFE
hT4/1-578	- QAEVLIFLDANCECFNGWLEFLLARIAEDNIVVSFDIVIDUNIFEFANFVQR-GKVNSKGNFDWSLIFGWEILFFMENQK-KKDEIFFINSFFAGULFSIFKSTFE - TGDVITFLYCHCFCNSGWIFPLLFRIGRYFTAVVCPVIDTIDWNTFFFYMOIGFPMIGGFBWRITFOWHSVPKOFRDR-RISRIDVSKKYFO
hT12/1-581	- T GDV LT FLYCHCECNSGWLEP LLER I GRYETAVVCPV I DT I DWNTFEPYMQ I G E PM I GG FDWR LT FQWH SVPKQERDR - R I SR I DP I RSPTMAGGL FAV SKKY FQ - RGDV LT FLDCHCECHEGWLEP LLQR I HEEE SAVVCPV I DV I DWNT FEYLGN SG E PQ I GG FDWR LV FTWHT VPERER I R-MQSP VDV I RSPTMAGGL FAV SKKY FE
hT1/1-559	K GQV ITFLDAHCECT VGWLEPLLAR I KHDRRT VVCPI I DVI S DDTFEYMAGS DMTY GGFNWKLN FRWYPV POR EMDRRKGDRT LPVRTPTMAGGLFSI DRDY PO - K GQV I TFLDAHCECT LGWLEPLLAR I KEDRKT VVCPI I DVI S DDTFEYMAGS DMTY GGFNWKLN FRWYPV POR EMDRRKGDRT LPVRTPTMAGGLFSI DRDY FE
hT13/1-556	- K GQ V I T F L DAHC ECT L GW L EP L L AR I K E D R K T V V C P I I D V I S D D T F E YMAG S D M T Y GG F N W K L N F R W Y P V P Q R EMD R R K G D R T L P V R T P T M A G G L F S I D R N Y F E
hT2/1-571 hT14/1-552	- QAK V LTFLDSHCECNEHWLEPLLER VAEDRTRVVSPIIDVINMDNFQYVGASADLKGGFDWNLVFKWDYMTPEQRRSRQGNPVAPIKTPMIAGGLFVMDKFYF - QGTTLTFLDSHCEVNRDWLQPLLHRVKEDYTRVVCPVIDIINLDTFTYIESASELRGGFDWSLHFQWEQLSPEQKAR-RLDPTEPIRTPIIAGGLFVIDKAWFD
hT16/1-552	-QGTILTFLDSHCEVNKUWLQFLLHNVKEDTIKVVCFVIDTINUDTFTTEDSASELKGGFDWSLHFQWEQLSFEQKAK-KLDFTEFIKTFTIAGGLFVIDKNWFN - AATVITFLDSHCEVNKUWLQFLLHNVKEDTIKVVCFVIDTINUDTSLDNFAVLAASSELKGGFDWSLHFKWEQLSFEQKAK-KLDFTEFIKTPTIAGGLFVIDKNWFN
11120/1-550	
	770 780 790 800 810 820 830 840 850 860 870
hT8/1-637	EIGSLÖGGMLIVGGENVELSLRVWQCGGKVEILPCSRIAHLERHHKPYALDLTAALKRNALRVÅEIWMDEHKHMVYLAWNIPL-QNSGIDFGDVSSRMALREKL
hT18/1-607	EIGLLDEGMEVYGGENVELGIRVWQCGGSVEVLPCSRIAHIERAHKPYTEDLT-AHVRRNALRVAEVWMDEKSHVYMAWNIPQ-EDSGIDIGDITARKALRKQL DIGLLDPGMEVYGGENVELGMEVWQCGGSMEVLPCSRVAHIERTKPYNNDID-YYAKRNALRAAEVWMDDYKSHVYMAWNIPM-SNPCVDFGDVSERALRKQL EIGLLDPGMDYYGGENIELGIKVWLCGSMEVLPCSRVAHIERKKPYNSNIC-YTYKNALRVAEVWMDDYKSHVYIAWNIP-NPCIDIGDVSERALRKSL
hT9/1-603	DIGLLDPGMEVYGGENVELGMRVWQCGGSMEVLPCSRVAHIERTRKPYNNDIDYYAKRNALRAAEVWMDDFKSHVYMAWNIPM-SNPGVDFGDVSERLALRQRL
hT19/1-598 hT10/1-603	EIGLUDPGMDVYGGENTELGIKVWLCGGSMEVLPCSRVAHIERKKKPYNSNIGFYTKRNALRVAEVWMDDYSSHVYJAWNLPL-ENPGIDIGDVSERRALRSL
hT17/1-584	E L G GY DP G L E I W G G E QY E I S F K V WM C G G R M E D I P C S R V G H I Y R K Y V P Y K V P A G V S L A R N L K R V A E V WM D E Y A E Y I Y Q R R P E Y R H L S A G D V A V Q K K L R S S L E L G G Y D P G L E I W G G E Q Y E I S F K V WM C G G E M F D V P C S R V G H I Y R K Y V P Y K V P S G T S L A R N L K R V A E T WM D E F A E Y I Y Q R R P E Y R H L S T G D I S A Q K E L R K Q L
hT7/1-657	ELGLYD YD CEL WIDDECH EI SY KWWCDGEM FUY CSAVUM FFRAN YP AV FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
hT5/1-940	ELGTYDPGLDVWGGENMELSFKVWMCGGEIEIIPCSRVGHIFRNDNPYSFPKDRMKTVERNLVRVAEVWLDEYKELFYGHGDHLIDQGLDVGNLTQQRELRKKL
hT11/1-608	ELGQYDSGMDIWGGENLEISFRIWMCSGKLSIIPCSRVGHIFRKRRPYGSPEGQD-TMTHNSLRLAHVWLDEYKEQYFSLRPDLKTKSYGNISERVELRKKL
hT20/1-443 hT15/1-639	EI GQYDKDMDFWGRENLELSLRIWMGGGQLFIIPCSRVGHISKNQTGKP-STIIS-AMTHNYLRLVHVWLDEYKEQFFLRKPGLKVVTYGNIRREVELRKRL
hT3/1-633	NIGATOSENSERGENEELSTRAWELGGSVEIFFCSRVGHTFQROSHSFL===DQ==EATERNRVFLAETWELGFREIFTRISFEATSESR=AEKFDUNKELQERKE VIGSVDFEMFINGGENIENSERVNOCGOIFENDPCSVCHVERSKSPHSFP====KGTO-VIARNOVELAETVNLGFKEIFFRRNTDAEKTVLVKAEGDISKRFFLKHRI
hT6/1-622	Y I GSY DE EME IWGGEN I EMSFRVWQCGGQLE I MPCSVVGHVFRSK SPHSFP KGTQ - V I ARNQVR LA EVWMDEYKE I FYRRNTDAAK I V KQKAFGDLSK RFÊ I KHRL H I GTYDNQME I WGGEN VEMSFRVWQCGGQLE I I PCSVVGHVFRTK SPHTFP KGTQ - V I ARNQVR LA EVWMDSYKK I FYRRNLQAAKMAQEK SFGDI SERLQL REQL
hT4/1-578	Y L G T Y D T G M F V W G G F N I F I S F R V W O C G G K I F I H P C S H V G H V F P K R A P Y A R P N F I O N T A R A A F V W M D F Y K F H F Y N R N P P A R K F A Y G D I S F R K I I R F R I
hT12/1-581	Y LG SY DT GMEVWGG ENLEFSFRIWQC GGVLETHPCSHVGHVFPKQAPYSRNKALANSVRAA EVWMDEFKELYYHRNPRARLEPFGDVT ERKQLRDKL EIGTYDAGMDIWGG ENLEISFRIWQC GGTLEIVTCSHVGHVFRKATPYTFPGGTGQIINKNNRR LA EVWMDEFKNFFYIISPGVTKVDYGDISSRVGLRHKL
hT1/1-559	EIGTYDAGMDIWGGENLEISFRIWQCGGTLEIVTCSHVGHVFRKATPYTFPGGTGQIINKNNRRLAEVWMDEFKNFFYIISPGVTKVDYGDISSRVGLRHKL
hT13/1-556 hT2/1-571	E I GTY DAGMD I WGGENLEMSFR I WQCGGSLE I VTCSHVGHV FRKATPYTFPGGTGHV I NKNNRR LAEVWMDE FKDFFY I I SPGVVKVDYGDVSVRKTLRENL ELGKYDMMMDVWGGENLE I SFRVWQCGGSLE I I PCSRVGHV FRKQHPYTFPGGSGTV FARNTRRAAEVWMDEYKNFYYAAVPSARNVPYGNIQSRLELRKKL
hT14/1-552	ELGKTUMMMDVWGGENELEISFKVWQGGSLEIJPGSKVGNVFKQHPTFFFGGSGIVFARNIKKAAEVWMDFKNFTTAAVFSAKNVFTGNUSSELEKKL YIGKYDMDMDIWGGENELEISFKVWQGGSLEIJPGSRVGHVFKKHPVVFFKEHPVFFPGGSGIVFARNIKKAAEVWMDFYVOVYAAPFFALFRPFGNUSSELEKKL
hT16/1-558	Y L G KY DMDMD I WG G E N F E I S F R V WN G G S L E I V P C S R V G H V F R K K H P Y V F P D G NA NT Y I K NT K R T A E V M M D E Y KQ Y Y Y A A R P F A L E R P F G N V È S R L D L R K N L H L G KY D A Q M D I WG G E N F L S F R V WN C G G S L E I V P C S R V G H V F R K R H P Y N F P E G N A L T Y I R NT K R T A E V WM D E Y KQ Y Y Y A A R P F A L G K A F G S V A T R I E Q R K K M
	<u>880</u> <u>890</u> <u>900</u> <u>910</u> <u>920</u> <u>930</u> <u>940</u> <u>950</u> <u>960</u> <u>970</u> <u>980</u>
hT8/1-637	KCKT FDWYLKNYYP LLKPLHTI
hT18/1-607	Q C K T F R WY L V S V Y P E M R M Y S D I I A Y G V L Q N S L K T D L C L D Q G P D T E N V P I M Y I C H G M T P Q N V Y Y T S S Q Q I H V G I L S P T V D D
hT9/1-603	K C R S F KWY L E NVY P EMR VY NNT L T Y G E V R N S K A SAY C L D Q G A E D G D R A I L Y P C H G M S Q L V R Y S A D G L L Q L G P L G S T A F L
hT19/1-598 hT10/1-603	
hT17/1-584	K CK DF KW FMA AV MOV PK YV P
hT7/1-657	NCQ 5 F KW F M E E I A Y D I T S H Y P L P P K N V D W G E I R G F E T - A Y C I D S M G K T N G G F V E L G P C H R M G G N Q L F R I N E A N Q L M Q Y
hT5/1-940	K C K S F K WY L E N V F P D L R A P I V R A
hT11/1-608	GCK S FKWY LDNVY P EMQ I SGSHAK PQQ P I FVNR GP K R P K V LQR GR L Y HLQ T - NK C L V AQG R P SQK GG L V V LK AC D Y S D P NQ I W I Y N E E H E L V L N S
hT20/1-443 hT15/1-639	
hT3/1-633	GCK I FMW LANVI FELTFSEFKF
hT6/1-622	HCHNF SWY LINVYP EMFYP DLTPTFYGAIKNLGT-NOCLDVGENNRGGRPLIMYSCHGLGGNOYF EYTTORDLRHNIAK
hT4/1-578	R C K S F DWY L K N V F P N L H V P E D R P
hT12/1-581	Q C K D F K W F L E T V Y P E L H V P E D R P
hT1/1-559	Q C K P F SWY L E N I Y P D SQ I P R H Y F
hT13/1-556 hT2/1-571	KCKPFSWYLEN YPDSQTPKKYYS-LGETNVET-NQCLDNMGKKENEKVGTFNCHGMGGNQVFSYTADKETKTD
hT14/1-552	R CO S F KWY L EN Y P ELS I P K S S
hT16/1-558	NCK S FRWY LENVY PELTVP VK EAL-PGIIKQG-VNCLESQGQNTAGDFLLGMGICR GSAKNPQPAQAWLF SDHL-IQQQ
	BNO BNO POO PIO PZO PIO PAO PSO PSO PRO
hT8/1-637	
	990 1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 ASDRCLTDPGKAEKPTLEPCSKAAKNRLHIYWDFKPG-GAVINRDTKRCLEMKKDLL-GSHVLVLQTCSTQVWEIQHTVRDWGQT
hT18/1-607	DDNRCLVDVNSRPRLIECSYAKAKRMKLHWQFSQG-GPIQNRKSKRCLELQENSDLE-FGFQLVLQKCSGQHWSITNVLRSLAS-
hT9/1-603	DDNRCLVDVNSRPRLIECSYAKAKRMKLHWQFSQG-GPIQNRKSKRCLELQENSDLE-FGFQLVLQKCSGQHWSITNVLRSLAS-
hT9/1-603 hT19/1-598 hT10/1-603	DDNRCLVDVNSRPRLIECSYAKAKRMKLHWQFSQG-GPIQNRKSKRCLELQENSDLE-FGFQLVLQKCSGQHWSITNVLRSLAS-
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584	DDNRCLVDVNSRPRLIECSYAKAKRMKLHWQFSQG-GPIQNRKSKRCLELQENSDLE-FGFQLVLQKCSGQHWSITNVLRSLAS-
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657	DDNRCLVDVNSRPRLIECSYAKAKAMKLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQLWMSITNVLRSLAS- PDSKCLVDDGTCRMWFTLKRCEDVAR-PTQRLWDFTQS-CPIVSRATGRCLEVENKGA-L-AGLDLILKSCTGQLWMIKNWIKHARH- PDTRCLVDN
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940	DDNRCLVDVNSRPRLIECSYAKAKAMKLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQLWMSITNVLRSLAS- PDSKCLVDDGTCRMWFTLKRCEDVAR-PTQRLWDFTQS-CPIVSRATGRCLEVENKGA-L-AGLDLILKSCTGQLWMIKNWIKHARH- PDTRCLVDN
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT15/1-639	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT15/1-639 hT3/1-633	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT15/1-639 hT3/1-633 hT6/1-622	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT7/1-637 hT5/1-638 hT20/1-443 hT15/1-638 hT6/1-622 hT4/1-578 hT12/1-581	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT15/1-639 hT3/1-633 hT6/1-622 hT4/1-578 hT12/1-581 hT12/1-581	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-584 hT7/1-657 hT5/1-940 hT15/1-639 hT3/1-633 hT6/1-622 hT4/1-578 hT12/1-581 hT12/1-556	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT5/1-639 hT3/1-633 hT6/1-632 hT6/1-578 hT12/1-581 hT12/1-581 hT13/1-559 hT13/1-559	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-598 hT17/1-584 hT7/1-657 hT5/1-639 hT3/1-633 hT15/1-639 hT3/1-633 hT6/1-622 hT4/1-578 hT12/1-581 hT12/1-559 hT13/1-556	DDNRCLVDVNS RPRLIECSYAK KRMMLLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQWMSITNVLRSLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-603 hT17/1-584 hT7/1-657 hT5/1-940 hT11/1-608 hT20/1-443 hT5/1-639 hT3/1-633 hT6/1-632 hT6/1-578 hT12/1-581 hT12/1-581 hT13/1-559 hT13/1-559	DDNRCLVDVNSRPRLIECSYAKAKAMKLHWQFSQG-CPIQNRSTARCLELQENSDLE-FGFQLVLQKCSCQLWMSITNVLRSLAS- PDSKCLVDDGTCRMWFTLKRCEDVAR-PTQRLWDFTQS-CPIVSRATGRCLEVENKGA-L-AGLDLILKSCTGQLWMIKNWIKHARH- PDTRCLVDN
hT9/1-603 hT19/1-598 hT10/1-598 hT17/1-584 hT7/1-657 hT5/1-639 hT3/1-633 hT15/1-639 hT3/1-633 hT6/1-622 hT4/1-578 hT12/1-581 hT12/1-559 hT13/1-556	DDNRLUDD
hT9/1-603 hT19/1-598 hT10/1-638 hT17/1-554 hT7/1-554 hT7/1-657 hT7/1-640 hT11/1-600 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-449 hT10/1-540 hT10/1-558 hT12/1-558 hT16/1-558	DDNRCLVDVNS PRELIECSYAK AKAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-638 hT17/1-554 hT7/1-554 hT7/1-557 hT5/1-940 hT11/1-663 hT6/1-623 hT6/1-623 hT6/1-558 hT16/1-558 hT6/1-558 hT16/1-558	DDNRCLVDVNS PRELIECSYAK AKAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-638 hT17/1-554 hT7/1-554 hT7/1-554 hT7/1-940 hT11/1-604 hT11/1-603 hT12/1-419 hT12/1-419 hT12/1-518 hT12/1-518 hT12/1-558 hT12/1-558 hT12/1-558	DDNRCLVDVNSPRELIECSYAKAKRMCLHWQFSQC-CPIQNR+TSKRCLELQENSDLE-FGFQLVLQKCSCQUWKSITAVLKSLAS- PDSKCLVDDCGKUKILWGTTSKC-DFVISCQUWSITAVLKSTAS
hT9/1-603 hT19/1-598 hT10/1-638 hT17/1-554 hT7/1-554 hT7/1-557 hT5/1-940 hT11/1-663 hT6/1-623 hT6/1-623 hT6/1-558 hT16/1-558 hT6/1-558 hT16/1-558	DDNRCLVDVNSRPRLIECSYAKAKAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-639 hT17/1-554 hT17/1-554 hT7/1-657 hT7/1-657 hT7/1-639 hT17/1-639 hT17/1-639 hT17/1-639 hT17/1-639 hT17/1-558 hT16/1-558 hT16/1-558	DDNRCLVDVNSPRELIECSYAKAKRMCLHWQFSQC-CPIQNR+TSKRCLELQENSDLE-FGFQLVLQKCSCQUWKSITAVLKSLAS- PDSKCLVDDCGKUKILWGTTSKC-DFVISCQUWSITAVLKSTAS
hT3/1-603 hT13/1-538 hT10/1-638 hT17/1-546 hT17/1-546 hT17/1-546 hT17/1-648 hT10/1-648 hT10/1-648 hT10/1-648 hT10/1-648 hT16/1-578 hT16/1-558 hT16/1-558 hT16/1-558 hT16/1-558 hT16/1-558 hT16/1-558 hT19/1-637 hT18/1-637 hT18/1-6437 hT1	DDNRCLVDVNSRPRLIECSYAK
hT9/1-603 hT19/1-598 hT10/1-638 hT17/1-554 hT7/1-554 hT7/1-554 hT7/1-639 hT15/1-9408 hT15/1-6439 hT15/1-6439 hT16/1-622 hT4/1-558 hT12/1-558 hT16/1-558 hT16/1-558 hT16/1-558	DDNRCLVDVNS RPRLIECSYAK AKAMKLHWQF3QC-CPIQN
hT3/1-603 hT13/1-538 hT10/1-637 hT17/1-546 hT17/1-546 hT17/1-546 hT17/1-647 hT11/1-668 hT10/1-643 hT15/1-639 hT15/1-639 hT13/1-558 hT16/1-568 hT16/1-568 h	DDNRCLVDVNSRPRLIECSYAKAKPMCLHWQFSQC-CPIQNRFSRCLELQENSDLE-FGCQLVLQKCSCQKWKSITAVLRSLAS- PDSKCLVDN
hT9/1-603 hT19/1-598 hT10/1-637 hT7/1-578 hT7/1-647 hT7/1-647 hT7/1-647 hT11/1-668 hT10/1-643 hT10/1-643 hT10/1-643 hT1/1-639 hT1/1-639 hT1/1-558 hT1/1-558 hT1/1-557 hT18/1-603 hT1/1-558 hT16/1-558 hT16/1-558 hT16/1-643 hT10/1-643	DDNRCLVDVNS RPRLIECSYAK AKAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-633 hT10/1-633 hT10/1-657 hT17/1-547 hT17/1-647 hT11/1-668 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643 hT10/1-643	DDNRCLVDVNSRPRLIECSYAKAKRMKLHWQF3QC-CPIQNRSKRKCLELQENSDLE-FGFQLVLQKCSCQKWMSITAKLAS- PDSKCLVDN
hT9/1-603 hT19/1-538 hT10/1-638 hT10/1-638 hT17/1-554 hT17/1-554 hT17/1-637 hT11/1-608 hT10/1-648 hT10/1-648 hT10/1-649 hT14/1-578 hT14/1-558 hT16/1-558 h	DDNRCLVDVNSRPRLIECSYAKAKPMCLHWQF3QC-CPIQNRFTRKCLELQENSDLE-FGFQLVLQKCSCQKWKSITAVLRSLAS- PDSKCLVDN
hT9/1-603 hT19/1-598 hT10/1-639 hT10/1-637 hT17/1-546 hT17/1-546 hT17/1-649 hT11/1-668 hT10/1-649 hT10/1-649 hT10/1-627 hT11/1-628 hT10/1-629 hT11/1-558 hT10/1-558 hT10/1-558 hT10/1-649 h	DDNRCLVDVNSRPRLIECSYAK
hT9/1-603 hT19/1-538 hT10/1-638 hT10/1-638 hT17/1-554 hT17/1-554 hT17/1-639 hT11/1-608 hT10/1-468 hT10/1-468 hT10/1-639 hT11/1-639 hT11/1-639 hT11/1-538 hT16/1-558 hT16/1-558 hT16/1-558 hT16/1-558 hT16/1-558 hT17/1-554 hT16/1-558 h	DDNRCLVDVNSRPRLIECSYAKAKEMACLHWQF3QC-CPIQNR-TARKCLELQENSDLE-FGFQLVLQKCSCQKWMSITAKLAS- PDSKCLVDD
hT9/1-603 hT19/1-598 hT10/1-639 hT10/1-637 hT17/1-546 hT17/1-546 hT17/1-649 hT11/1-668 hT10/1-649 hT10/1-649 hT10/1-627 hT11/1-628 hT10/1-629 hT11/1-558 hT10/1-558 hT10/1-558 hT10/1-649 h	DDNRCLVDVNSRPRLIECSYAKKRAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-639 hT17/1-546 hT17/1-546 hT17/1-546 hT17/1-649 hT11/1-608 hT10/1-649 hT15/1-639 hT15/1-639 hT16/1-528 hT16/1-578 hT16/1-558 h	DDNRCLVDVNSRPRLIECSYAKARMMLLHWQF3QC-CPIQNRFXRCLELQENSDLE-FGCQLVLQRCSCQKWMSITAVLRSLAS- PDSKCLVDN
hT9/1-603 hT19/1-598 hT10/1-637 hT17/1-547 hT17/1-647 hT17/1-647 hT11/1-668 hT10/1-649 hT10/1-649 hT11/1-608 hT10/1-628 hT10/1-628 hT10/1-628 hT10/1-628 hT10/1-628 hT10/1-559 hT13/1-556 hT10/1-558 hT10/1-643 hT10/1-555 h	DDNRCLVDVNSRPRLIECSYAKKRAMKLHWQF3QC-CPIQN
hT9/1-603 hT19/1-598 hT10/1-639 hT17/1-546 hT17/1-546 hT17/1-546 hT17/1-649 hT11/1-608 hT10/1-649 hT15/1-639 hT15/1-639 hT16/1-528 hT16/1-578 hT16/1-558 h	DDNRCLVDVNSRPRLIECSYAKARMMLLHWQF3QC-CPIQNRFXRCLELQENSDLE-FGCQLVLQRCSCQKWMSITAVLRSLAS- PDSKCLVDN

Figure S2. Alignment of human GalNAc-T genes. Amino acid sequences corresponding to full-length human GALNT1–GALNT20 (Table S1) were aligned using Clustal Omega.³ GalNAc-Ts are labeled as follows: hT8(human GalNAc-T8)/1-637 (sequence contains 637 amino acids).

Human gene name	Accession number ^a
GALNT1	X85018
GALNT2	X85019
GALNT3	X92689
GALNT4	Y08564
GALNT5	NM_014568 ^b
GALNT6	Y08565
GALNT7	AJ002744
GALNT8	AJ271385
GALNT9	AB040672
GALNT10	AJ505950
GALNT11	Y12434
GALNT12	AJ132365
GALNT13	AJ505991
GALNT14	Y09324
GALNT15	NM_054110
GALNT16	AJ505951
GALNT17	AJ626725
GALNT18	AJ626724
GALNT19	AJ626726
GALNT20	145292

Table S1. GalNAc-T gene names and accession numbers.

⁽a) GalNAc-T amino acid sequence and accession information is summarized in Bennett et al.⁴

⁽b) Reported in Guo et al.⁵






Figure S3. GalNAc-T2 with a GalNAc-peptide, MUC5AC-13, bound to the lectin domain. GalNAc-T2 (gray; active confirmation of the enzyme, co-crystallized with UDP and MUC5AC-13, PDB ID: 5AJP). (A) GalNAc (sticks) is attached to MUC5AC-13 (orange sticks and surface) at Thr13. The GalNAc methyl group (teal stick) extends out of the pocket formed by MUC5AC-13 and the lectin domain (light gray surface) into a solvent-exposed cleft between the acceptor peptide and the lectin and catalytic domains (dark gray surface). (B) View of the solvent exposed cleft into which GalNAc methyl extends. GalNAc (sticks) bound to Thr13 of MUC5AC-13 (orange sticks) is shown.





represent the mean of technical triplicates, and the error bars represent the standard deviation.




Figure S5. T1(I238A/L295A) activity assay with UDP-GalNAc analogs.

Glycosylation reaction by 25 nM T1(I238A/L295A) with 500 μ M UDP-GalNAc analog and 50.0 μ M peptide (GAGAFFPTPGPAGAGK) at 37 °C for 1 h. Enzymatic activity was measured using the Glycosyltransferase Activity Kit (R&D Systems, Inc.). All data represent the mean of technical triplicates, and the error bars represent the standard deviation.




Figure S6. Screening GalNAc-T2 for an orthogonal enzyme-substrate pair. Glycopeptide formation by wild-type and double mutant GalNAc-T2. Peptide-1 and UDP-GalNAc or UDP-GalNAc analogs were incubated with GalNAc-T2 at 37 °C for 1 h, and the reaction was quenched with aqueous EDTA (150 mM, pH = 8.0). The percent conversion to glycopeptide product was quantified by HPLC separation and peak integration. These data are the same as those shown in Figure 3C. All data represent the mean of technical triplicates, and the error bars represent the standard deviation.

Table S2. Synthetic gBlocks used for GalNAc-T1 and GalNAc-T10 gene assembly.

T1_GB1 ^c	GACAAGCTTGCGGCCGCGGATGAAAAAAGGAGAGAGAGAG
	TGCTGGAGATGTTCTAGAGCCAGTACAAAAGCCTCATGAAGGTCC
	TGGAGAAATGGGGAAACCAGTCGTCATTCCTAAAGAGGATCAAGA
	AAAGATGAAAGAGATGTTTAAAAATCAATCAGTTCAATTTAATGGC
	AAGTGAGATGATTGCACTCAACAGATCTTTACCAGATGTTAGGTTA
	GAAGGGTGTAAAACAAAGGTGTATCCAGATAATCTTCCTACAACA
	AGTGTGGTGATTGTTTTCCACAATGAGGCTTGGAGCACACTTCTGC
	GAACTGTCCATAGTGTCATTAATCGCTCACCAAGACACATGATAG
	AAGAAATTGTT <u>GAGACC</u> TGGTGTG
T1 GB2	GACAGGA <u>GGTCTC</u> ATTGTTCTAGTAGATGATGCCAGTGAAAGAGA
_	CTTTTTGAAAAGGCCTTTAGAGAGTTATGTGAAAAAACTAAAAGT
	ACCAGTTCATGTAATTCGAATGGAACAACGTTCTGGATTGATCAG
	AGCTAGATTAAAAGGAGCTGCTGTGTCTAAAGGCCAAGTGATCAC
	CTTCCTGGATGCCCATTGTGAGTGTACAGTGGGATGGCTGGAGCCT
	CTCTTGGCCAGGATCAAACATGACAGGAGAACAGTGGTGTGTCCC
	ATCATCGATGTGATCAGTGATGATACTTTTGAGTACATGGCAGGCT
	CTGATATGACCTATGGTGGGTTCAACTGGAAGCTCAATTTTCGCTG
	GTATCCTGTTCCCCAAAGAGAAATGGACAGAAGGAAAGGTGATCG
	GACTCTTCCTGTCAGGACACCTACCATGGCAGGAGGCCTTTTTTCA
	ATAGACAGAGATTACTTTT <u>GAGACC</u> TGGTGTG
T1 GB3	GACAGGAGGTCTCACTTTCAGGAAATTGGAACATATGATGCTGGA
_	ATGGATATTTGGGGAGGAGAAAACCTAGAAATTTCCTTTAGGATT
	TGGCAGTGTGGAGGAACTTTGGAAATTGTTACATGCTCACATGTTG
	GACATGTGTTTCGGAAAGCTACACCTTACACGTTTCCAGGAGGCA
	CAGGGCAGATTATCAATAAAAATAACAGACGACTTGCAGAAGTGT
	GGATGGATGAATTCAAGAATTTCTTCTATATAATTTCTCCAGGTGT
	TACAAAGGTAGATTATGGAGATATATCGTCAAGAGTTGGTCTAAG
	ACACAAACTACAATGCAAACCTTTTTCCTGGTACCTAGAGAATATA
	TATCCTGATTCTCAAATTCCACGTCACTATTTCTCATTGGGAGAGA
	TACGAAATGTGGAAACGAATCAGTGTCTAGATAACATGGCTAGAA
	AAGAGAATGAAAAAGTTGGA T <u>GAGACC</u> TGGTGTG
T1 GB4 ^d	GACAGGA <u>GGTCTC</u> ATGGAATTTTTAATTGCCATGGTATGGG <u>T</u> GGT
	AATCAGGTTTTCTCTTATACTGCCAACAAAGAAATTAGAACAGAT
	GACCTTTGCTTGGATGTTTCCAAACTTAATGGCCCAGTTACAATGC
	TCAAATGCCACCACCTAAAAGGCAACCAACTCTGGGAGTATGACC
	CAGTGAAATTAACCCTGCAGCATGTGAACAGTAATCAGTGCCTGG
	ATAAAGCCACAGAAGAGGATAGCCAGGTGCCCAGCATTAGAGACT
	GCAATGGAAGTCGGTCCCAGCAGTGGCTTCTTCGAAACGTCACCC
	TTCCAGAAATATTCTGAGA ATTCATCGATAG
L	

⁽c) BsaI restriction sites are underlined in each gBlock.

⁽d) Silent mutations in any gBlock are underlined and bold.

T10_GB1e	GACAGGA <u>GGTCTC</u> AGGCCGCGCCTGGGGGATCGGGGGGCGGCGGT
	GGCGCCGGCGGGGGGACAGGGCTCACACAGTCGACAAAAGAAAA
	CGTTTTTCTTGGGAGATGGGCAGAAGCTGAAGGACTGGCATGACA
	AGGAGGCCATCCGGAGGGACGCTCAGCGCGTAGGAAATGGAGAA
	CAAGGAAGACCTTACCCCATGACCGATGCTGAGAGAGTGGATCAG
	GCATACCGAGAAAATGGATTTAACATCTACGTCAGTGATAAAATC
	TCCTTGAATCGCTCTCTCCCAGATATCCGGCACCCAAACTGCAACA
	GCAAGCGCTACCTGGAGACACTTCCCAACACAAGCATCATCATCC
	CCTTCCACAACGAGGGCTGGTCCTCCCTCCTCCGCACCGTCCACAG
	TGTGCTCAATCGCTCGCCTCCAGAGCTGGTCGCCGAGATTGTACTG
	GTCGACGACTTCAGTGATCGAGAGCACCTGAAGAAGCCTCTTGAA
	GACTACATGGCCCTTTT <u>GAGACC</u> TGGTGTG
T10 GB2	GACAGGAGGTCTCACTTTTCCCCAGTGTGAGGATTCTTCGAACCAA
WT -	GAAACGGGAAGGGCTGATAAGGACCCGAATGCTGGGGGCCTCAG
	TGGCAACTGGGGATGTCATCACATTCTTGGATTCACACTGTGAAGC
	CAATGTCAACTGGCTTCCCCCCTTGCTTGACCGCATTGCTCGGAAC
	CGCAAGACCATTGTGTGCCCGATGAATGATGTAATTGACCATGAC
	GACTTTCGGTACGAGACACAGGCAGGGGATGCCATGCGGGGAGCC
	TTTGACTGGGAGATGTACTACAAGCGGATCCCGATCCCTCCAGAA
	CTGCAGAAAGCTGACCCCAGCGACCCATTTGAGTCTCCCGTGATG
	GCCGGTGGACTGTTCGCCGTGGATCGGAAGTGGTTCTGGGAACTC
	GGCGGGTATGACCCAGGCTTGGAGATCTGGGGAGGGGGGGG
	GAAATCTCCTTCAAGGTGTGGGATGTGTGGGGGGCCGCATGGAGGAC
	ATCCCCTGCTCCAGGGTGGGCCATATCTACAGGAAGTATGTGCCCT
	ACAAGGTCCCGGCCGGAGTCAGCCTGGCCCGGAACCTTAAGCGGG
	TGGCCGAAGTGTGGATGGATGGATGAGTACGCAGAGTTGAGACCTGGTG
	TG
T10 GB2	GACAGGAGGTCTCACTTTTCCCCAGTGTGAGGATTCTTCGAACCAA
MUT	GAAACGGGAAGGGCTGATAAGGACCCGAATGCTGGGGGCCTCAG
WIC I	TGGCAACTGGGGATGTCATCACACTTCTTGGATTCACACTGTGAAGC
	CAATGTCAACTGGCTTCCCCCCTTGCTTGACCGCATTGCTCGGAAC
	CGCAAGACCATTGTGTGCCCGATGGCCGATGTAATTGACCATGAC
	GACTTTCGGTACGAGACACAGGCAGGGGGGGGGGGGGGG
	TTTGACTGGGAGATGTACTACAAGCGGATCCCGATCCCTCCAGAA
	CTGCAGAAAGCTGACCCCAGCGACCCATTTGAGTCTCCCGTGATG
	GCCGGTGGAGCCTTCGCCGTGGATCGGAAGTGGTTCTGGGAACTC
	GGCGGGTATGACCCAGGCTTGGAGATCTGGGGAGGGGGGGG
	GAAATCTCCTTCAAGGTGTGGGATGTGTGGGGGGCCGCATGGAGGAC
	ATCCCCTGCTCCAGGGTGGGCCATATCTACAGGAAGTATGTGCCCT
	ACAAGGTCCCGGCCGGAGTCAGCCTGGCCCGGAACCTTAAGCGGG
	TGGCCGAAGTGTGGATGGATGAGTACGCAGAGTT <u>GAGACC</u> TGGTG
	TG

⁽e) GalNAc-T10 was assembled with T10_GB1, T10_GB2_WT, and T10_GB3 (wild-type) or T10_GB1, T10_GB2_MUT, and T10_GB3 (double mutant).

T10_GB3	GACAGGA <u>GGTCTC</u> AGAGTACATTTACCAGCGCCGGCCTGAATACC
	GCCACCTCTCCGCTGGGGATGTCGCAGTCCAGAAAAAGCTCCGCA
	GCTCCCTTAACTGCAAGAGTTTCAAGTGGTTTATGACGAAGATAGC
	CTGGGACCTGCCCAAATTCTACCCACCCGTGGAGCCCCCGGCTGC
	AGCTTGGGGGGGAGATCCGAAATGTGGGCACAGGGCTGTGTGCAGA
	CACAAAGCACGGGGCCTTGGGCTCCCCACTAAGGCTAGAGGGCTG
	CGTCCGAGGCCGTGGGGGGGGGGGCTGCCTGGAACAACATGCAGGTATT
	CACCTTCACCTGGAGAGAGAGGACATCCGGCCTGG <u>G</u> GACCCCCAGCA
	CACCAAGAAGTTCTGCTTTGATGCCATTTCCCACACCAGCCCTGTC
	ACGCTGTACGACTGCCACAGCATGAAGGGCAACCAGCTGTGGAAA
	TACCGCAAAGACAAGACCCTGTACCACCCTGTCAGTGGCAGCTGC
	ATGGACTGCAGTGAAAGTGACCATAGGATCTTCATGAACACCTGC
	AACCCATCCTCTCACCCAGCAGTGGCTGTTTGAACACACCAACT
	CAACAGTCTTGGAAAAATTCAATAGGAACTGAG
	AATTTGAGACCTGGTGTG




Figure S7. Purified soluble GalNAc-Ts. (A) SDS-PAGE of GalNAc-T2 (predicted MW of the wild-type enzyme 61.6 kDa), GalNAc-T1 (63.1 kDa) and GalNAc-T10 (65.9 kDa) preparations (Coomassie stain). GalNAc-Ts are labeled wild-type (WT), single mutant (I253A, L310A), or double mutant (DM). Asterisks depict potential degradation products. (B) Western blot with anti-FLAG[®] immunolabeling.

II. General Information

MUC5AC-3 (GTT*PSPVPTTSTTSAP), MUC5AC-13 (GTTPSPVPTTSTT*SAP), EA2 (PTTDSTTPAPTTK), and a peptide optimized for GalNAc-T2 (GAGAPGPTPGPGAG) were purchased from AnaSpec, Inc. and used without further purification. A peptide optimized for GalNAc-T1 (GAGAFFPTPGPAGAGK) was synthesized on 2-chlorotrityl chloride resin by solid phase peptide synthesis using *N*-Fmoc-protected amino acids. Peptide concentrations were determined by amino acid analysis at the UC Davis Molecular Structure Facility. UDP-sugar concentrations were quantified using the molar extinction coefficient of UDP at 262 nm (10,000 $M^{-1}cm^{-1}$).

MacPyMOL was used to model all crystal structures. Integrated DNA Technologies (IDT) synthesized all gBlocks. Primer synthesis and sequencing of all plasmids prior to use was by Elim Biopharmaceuticals, Inc. (Hayward, USA). Restriction enzymes, Antarctic phosphatase, and T4 DNA ligase were purchased from New England Biolabs and used according to the manufacturer's instructions. PfuUltra II Fusion HS DNA polymerase was from Agilent. cOmpleteTM mini EDTA-free protease inhibitor, p3xFLAG-CMV-8, pFLAG-myc-CMV-19, recombinant human serum albumin, anti-FLAG[®] M2 agarose resin, and monoclonal anti-FLAG[®] M2 antibody were purchased from Sigma-Aldrich (now Millipore-Sigma). Colloidal Blue Staining Kit was obtained from Thermo Fisher Scientific.


Dulbecco's Modified Eagle Medium with high glucose (DMEM), Dulbecco's Phosphate-Buffered Saline without calcium or magnesium (DPBS), and Penicillin/Streptomycin were purchased from Hyclone. Fetal bovine serum (FBS) was obtained from Omega Scientific, and 0.25% trypsin/EDTA and Opti-MEM[®] Reduced Serum Medium were purchased from Invitrogen. TransIT[®]-293 transfection reagent was purchased from Mirus Bio LLC.

Chemical reagents were obtained from commercial sources and used without further purification unless otherwise noted. Unless stated otherwise, reactions were conducted under an atmosphere of nitrogen using anhydrous solvents. THF and CH_2Cl_2 were deoxygenated and dried by sparging with nitrogen followed by passage through an activated alumina column prior to use. Deionized water (18.2 M Ω .cm) was prepared by a Millipore Milli-Q Biocel A10 purification unit and used to prepare all buffers and aqueous solutions.


Glycosyltransferase Activity Kit was purchased from R&D Systems, Inc., and absorbance at 620 nm was acquired using a Molecular Devices SpectraMax M3 96-well plate reader. High-performance liquid chromatography (HPLC) analyses were carried out on an Agilent 1100 series system with an Agilent Poroshell 120 EC-C18 column (length 150 mm, I.D. 4.6 mm) at 40 °C with a solvent flow rate of 0.4 mL/min using a UV detector operating at 340 nm. Glycosylation sites were analyzed by an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC with an EASY-SprayTM LC 100 Å C18 column (length 150 mm, I.D. 75 μm).

Analytical thin layer chromatography (TLC) was performed with Silicycle 60 Å silica gel plates and analyzed by UV illumination or KMnO₄ stain. Flash column chromatography was performed using silica gel (60 Å pore size, 40–63 µm, 230–400 mesh). Preparative HPLC was performed on a Varian ProStar system with an Agilent Microsorb 100-5 C18 column (length 250 mm, I.D. 21.4 mm) or an Agilent prep 100 Å C18 column (length 250 mm, I.D. 21.2 mm) with a solvent flow rate of 20 mL/min. ¹H NMR, ¹³C NMR, and ³¹P NMR data were collected on a Varian Inova 500 MHz spectrometer at ambient temperature.

III. Glycosyltransferase Enzymatic Activity Assays (Figures S4, S5, S6, 3, 5A, and 5B)




Glycosylation by T2(I253A/L310A) with UDP-GalNAc analogs (Figure S4). The glycosylation reaction was initiated by the addition of T2(I253A/L310A) (50.0 nM) in Tris-HCl buffer (16.7 mM Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 25.0 μ L) to the mixture of UDP-GalNAc analog (500 μ M), peptide (GAGAPGPTPGPGAG; 100 μ M), and Coupling Phosphatase 1 (4 ng/ μ L) in Tris-HCl buffer (25 mM Tris-HCl, 20 mM MnCl₂; 25.0 μ L) at 0 °C, resulting in a final reaction mixture containing T2(I253A/L310A) (25.0 nM), peptide (50.0 μ M), UDP-GalNAc analog (250 μ M), and Coupling Phosphatase 1 (2 ng/ μ L) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl₂, 50 mM NaCl, 12.5% glycerol, pH = 7.4; 50.0 μ L). The glycosylation was conducted at 37 °C for 1 h. The enzymatic activity was measured according to the manufacturer's protocol (Glycosyltransferase Activity Kit; R&D Systems, Inc.).




Glycosylation by T1(I238A/L295A) with UDP-GalNAc analogs (Figure S5).

The glycosylation reaction was initiated by the addition of T1(I238A/L295A) (50.0 nM) in Tris-HCl buffer (16.7 mM Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 25.0 μ L) to the mixture of UDP-GalNAc analog (1.00 mM), peptide (GAGAFFPTPGPAGAGK; 100 μ M), and Coupling Phosphatase 1 (4 ng/ μ L) in Tris-HCl buffer (25 mM Tris-HCl, 20 mM MnCl₂; 25.0 μ L) at 0 °C, resulting in a final reaction mixture containing

T1(I238A/L295A) (25.0 nM), peptide (50.0 μ M), UDP-GalNAc analog (500 μ M), and Coupling Phosphatase 1 (2 ng/ μ L) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl₂, 50 mM NaCl, 12.5% glycerol, pH = 7.4; 50.0 μ L). The glycosylation was conducted at 37 °C for 1 h. The enzymatic activity was measured according to the manufacturer's protocol (Glycosyltransferase Activity Kit; R&D Systems, Inc.).




Characterization of Peptide-1 glycosylation products of GalNAc-T2 with UDP-GalNAc and analogs (Figures S6 and 3).



1-Peptide-1.

The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 12.2$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₁H₁₁₀N₂₂O₂₈: 859.3930, found: 859.3926 (-0.46 ppm).




 $R = \frac{1}{2} N_3$

2-Peptide-1.


The product formation was determined by HPLC (20% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 33.6$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₁H₁₀₉N₂₅O₂₈: 879.8937, found: 879.8928 (-1.02 ppm).



(S)-3-Peptide-1.


The product formation was determined by HPLC (21.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 27.2$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₂H₁₁₁N₂₅O₂₈: 886.9015, found: 886.9015 (-0.02 ppm).



$$R = \underbrace{\underbrace{}_{Et}^{N_3}}_{Et}$$

(S)-4-Peptide-1.

The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 30.2$ min. MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₇₃H₁₁₃N₂₅O₂₈: 893.9093, found: 893.9088 (-0.61 ppm).




 $R = k^{s} N_3$

7-Peptide-1.


The product formation was determined by HPLC (21% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 29.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₂H₁₁₁N₂₅O₂₈: 886.9015, found: 886.9011 (-0.47 ppm).




11-Peptide-1.

The product formation was determined by HPLC (21% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 26.1$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₄H₁₁₂N₂₂O₂₈: 878.4008, found: 878.4016 (+0.89 ppm).



(*R*)-12-Peptide-1.


The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 22.6$ min. MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₇₅H₁₁₄N₂₂O₂₈: 885.4086, found: 885.4092 (+0.63 ppm).



(S)-12-Peptide-1.


The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 21.9$ min.


MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₅H₁₁₄N₂₂O₂₈: 885.4086, found: 885.4090 (+0.40 ppm).



13-Peptide-1.

The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 21.8$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₅H₁₁₄N₂₂O₂₈: 885.4086, found: 885.4086 (-0.05 ppm).






R = jss

(*R*)-14-Peptide-1.


The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 30.4$ min. MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₇₆H₁₁₆N₂₂O₂₈: 892.4165, found: 892.4164 (-0.08 ppm).




(S)-14-Peptide-1.

The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 30.5$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₆H₁₁₆N₂₂O₂₈: 892.4165, found: 892.4172 (+0.82 ppm).




Characterization of Peptide-2 glycosylation products of GalNAc-T1 with UDP-GalNAc and analogs (Figures 5A and 5B).



1-Peptide-2.


The product formation was determined by HPLC (30% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 25.8$ min. MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₈₂H₁₁₈N₂₂O₂₈: 929.4243, found: 929.4242 (-0.10 ppm).



R = 3

13-Peptide-2.

The product formation was determined by HPLC (30% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 42.1$ min. MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₈₆H₁₂₂N₂₂O₂₈: 955.4399, found: 955.4413 (+1.42 ppm).




Characterization of Peptide-3 glycosylation products of GalNAc-T10 with UDP-GalNAc and analogs (Figures 5A and 5B).



1-Peptide-3.

The product formation was determined by HPLC (21% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 18.2$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₈H₁₄₀N₂₂O₄₁: 1080.4773, found: 1080.4797 (+2.21 ppm).




13-Peptide-3.

The product formation was determined by HPLC (22.5% acetonitrile/water; 0.1% trifluoroacetic acid; 0.4 mL/min) with $t_r = 31.5$ min. MS (ESI) m/z ([M+2H]²⁺) calcd for C₉₂H₁₄₄N₂₂O₄₁: 1106.4930, found: 1106.4939 (+0.85 ppm).

IV. Glycosylation Reaction Kinetics (Table 1; Figure 5C)


General reaction conditions for GalNAc-T kinetics

The glycosylation reaction was initiated by the addition of GalNAc-T in Tris-HCl buffer (16.7 mM Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 35.0 μ L) to the mixture of UDP-sugar (31.2 μ M, 62.5 μ M, 125 μ M, 250 μ M, 500 μ M and 1.00 mM), and peptide (Peptide-1 (1, (*S*)-3, and 11) = 534 μ M; Peptide-1 (7, (*S*)-12, 13) = 500 μ M); Peptide-2 = 500 μ M; Peptide-3 = 532 μ M) in Tris-HCl buffer (25 mM Tris-HCl, 20 mM MnCl₂; 35.0 μ L) at 0 °C, resulting in a final reaction mixture containing GalNAc-T, UDP-sugar (15.6 μ M, 31.2 μ M, 62.5 μ M, 125 μ M, 250 μ M, and 500 μ M); Peptide-2 = 250 μ M; Peptide-1 (1, (*S*)-3, and 11) = 267 μ M; Peptide-1 (7, (*S*)-12, 13) = 250 μ M); Peptide-2 = 250 μ M; Peptide-3 = 266 μ M) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl₂, 50 mM NaCl, 12.5% glycerol, pH = 7.4; 70.0 μ L). The glycosylation was conducted at 37 °C. Aliquots were taken at 5, 10, and 15 min and quenched by the addition of aqueous EDTA (150 mM, pH = 8.0). The glycopeptide formation was analyzed by HPLC, and initial rates were calculated.




Determination of kinetic parameters for GalNAc-T2 with Peptide-1 (Table 1).


The reaction conditions differ from the general reaction conditions for GalNAc-T kinetics as described here. GalNAc-T concentrations were as follows: WT-T2 with 1 (initial = 8.33 nM, final = 4.17 nM); T2(I253A/L310A) with (*S*)-3 (initial = 8.59 nM, final = 4.30 nM); T2(I253A/L310A) with 7 (initial = 20.0 nM, final = 10 nM); T2(I253A/L310A) with 11 (initial = 8.59 nM, final = 4.30 nM); T2(I253A/L310A) with (S)-12 (initial = 20.0 nM, final = 10 nM); T2(I253A/L310A) with 13 (initial = 30.0 nM, final = 15.0 nM). These reactions had aliquots removed after 4, 8, and 12 min instead: T2(I253A/L310A)/7 and T2(I253A/L310A)/(S)-12.




Kinetics of WT-T2 with UDP-GalNAc (1). $k_{\text{cat}} = 0.813 \pm 0.017 \text{ s}^{-1}; K_{\text{m}} = 30 \pm 2 \text{ }\mu\text{M}; k_{\text{cat}}/K_{\text{m}} = 28 \text{ }\text{m}\text{M}^{-1} \text{ s}^{-1}.$




Kinetics of T2(I253A/L310A) with UDP-Sugar ((S)-3). $k_{cat} = 0.566 \pm 0.014 \text{ s}^{-1}; K_m = 43 \pm 4 \text{ }\mu\text{M}; k_{cat}/K_m = 13 \text{ }m\text{M}^{-1} \text{ s}^{-1}.$




Kinetics of T2(I253A/L310A) with UDP-Sugar (7). $k_{\text{cat}} = 0.61 \pm 0.03 \text{ s}^{-1}$; $K_{\text{m}} = 1.6 \text{ x} 10^2 \pm 2 \text{ x} 10^1 \text{ }\mu\text{M}$; $k_{\text{cat}}/K_{\text{m}} = 3.8 \text{ }\text{m}\text{M}^{-1} \text{ s}^{-1}$.




Kinetics of T2(I253A/L310A) with UDP-Sugar (11). $k_{\text{cat}} = 0.68 \pm 0.02 \text{ s}^{-1}; K_{\text{m}} = 56 \pm 6 \text{ }\mu\text{M}; k_{\text{cat}}/K_{\text{m}} = 12 \text{ }\text{m}\text{M}^{-1} \text{ s}^{-1}.$




Kinetics of T2(I253A/L310A) with UDP-Sugar ((S)-12). $k_{\text{cat}} = 0.84 \pm 0.05 \text{ s}^{-1}$; $K_{\text{m}} = 4.3 \text{ x} 10^2 \pm 5 \text{ x} 10^1 \text{ }\mu\text{M}$; $k_{\text{cat}}/K_{\text{m}} = 2.0 \text{ }\text{m}\text{M}^{-1} \text{ s}^{-1}$.




Kinetics of T2(I253A/L310A) with UDP-Sugar (13). $k_{cat} = 0.158 \pm 0.003 \text{ s}^{-1}; K_m = 2.6 \pm 0.8 \text{ }\mu\text{M}; k_{cat}/K_m = 61 \text{ }m\text{M}^{-1} \text{ s}^{-1}.$




Determination of kinetic parameters for GalNAc-T1 with Peptide-2 (Figure 5C). The reaction conditions differ from the general reaction conditions for GalNAc-T kinetics as described here. GalNAc-T concentrations were as follows: WT-T1 and **1** (initial = 100)



Kinetics of WT-1 with UDP-GalNAc (1). $k_{\text{cat}} = 0.551 \pm 0.008 \text{ s}^{-1}; K_{\text{m}} = 22.8 \pm 1.5 \text{ }\mu\text{M}; k_{\text{cat}}/K_{\text{m}} = 24.2 \text{ }\text{m}\text{M}^{-1} \text{ }\text{s}^{-1}.$




Kinetics of T1(I238A/L295A) with UDP-Sugar (13). $k_{cat} = 0.097 \pm 0.002 \text{ s}^{-1}; K_m = 22 \pm 2 \mu\text{M}; k_{cat}/K_m = 4.3 \text{ mM}^{-1} \text{ s}^{-1}.$




Determination of kinetic parameters for GalNAc-T10 with Peptide-3 (Figure 5C).

The reaction conditions differ from the general reaction conditions for GalNAc-T kinetics as described here. GalNAc-T concentrations were as follows: WT-T10 and **1** (initial = 6.18 nM, final = 3.09 nM); T10(I266A/L321A) and **13** (initial = 6.17 nM, final = 3.08

nM. For GalNAc-T10, UDP-sugar final concentrations were varied from 15.6 μ M to 250 μ M (31.2 μ M to 500 μ M initial concentrations).



Kinetics of WT-T10 with UDP-GalNAc (1). $k_{\text{cat}} = 0.956 \pm 0.019 \text{ s}^{-1}; K_{\text{m}} = 5.1 \pm 0.9 \text{ }\mu\text{M}; k_{\text{cat}}/K_{\text{m}} = 1.9 \text{ } \text{x} \text{ } 10^2 \text{ } \text{m}\text{M}^{-1} \text{ s}^{-1}.$



Kinetics of T10(I266A/L321A) with UDP-Sugar (13). $k_{\text{cat}} = 1.09 \pm 0.03 \text{ s}^{-1}$; $K_{\text{m}} = 12.7 \pm 1.6 \text{ }\mu\text{M}$; $k_{\text{cat}}/K_{\text{m}} = 85.4 \text{ }\text{m}\text{M}^{-1} \text{ s}^{-1}$.

V. UDP-Sugar Competition Experiment (Figure 4)

Procedure.


The glycosylation reaction was initiated by the addition of WT-T2 (50.0 nM) in Tris-HCl buffer (16.7 mM Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 35.0 μ L) to the mixture of UDP-GalNAc (500 μ M), UDP-GalNAc analog (500 μ M) and Peptide-1 ((DAA)GAGAPGPTPGPAGAGK; 100 μ M) in Tris-HCl buffer (25 mM Tris-HCl, 20 mM MnCl₂; 35.0 μ L) at 0 °C, resulting in a final reaction mixture containing WT-T2

(25.0 nM), UDP-GalNAc (250 μ M), UDP-GalNAc analog (250 μ M), and peptide (50.0 μ M) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl₂, 50 mM NaCl, 12.5% glycerol, pH = 7.4; 70.0 μ L). The glycosylation was conducted at 37 °C. Reaction progress was monitored by taking aliquots and quenching them by the addition of aqueous EDTA (150 mM, pH = 8.0). The ratio between the two glycopeptides was determined by HPLC.


VI. Glycosylation of Natural Peptide Substrates by GalNAc-Ts (Figure 6)

Procedure.

The glycosylation reaction was initiated by the addition of wild-type or double mutant GalNAc-T (-T2 = 60.0 nM; -T1 = 30.0 nM; -T10 = 200 nM) in Tris-HCl buffer (16.7 mM) Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 25.0 μ L) to the mixture of UDP-sugar (1 was used for WT-T2, -T1, -T10, and 13 was used for double mutant -T2, -T1, -T10; 1.00 mM), and peptide (MUC5AC-3, MUC5AC-13, or EA2; 200 µM) in Tris-HCl buffer (25 mM Tris-HCl, 20 mM MnCl₂; 25.0 µL) at 0 °C, resulting in a final reaction mixture containing wild-type or double mutant GalNAc-T (-T2 = 30.0 nM; -T1 = 15.0 nM; -T10 = 100 nM), UDP-sugar (1 was used for WT-T2, -T1, -T10, and 13 was used for double mutant -T2, -T1, -T10; 500 µM), and peptide (MUC5AC-3, MUC5AC-13, or EA2; 100 μM) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl₂, 50 mM NaCl, 12.5% glycerol, pH = 7.4; 50.0 μ L). The glycosylation was conducted at 37 °C. Reaction progress was monitored by taking aliquots and quenching them by the addition of aqueous EDTA (150 mM, pH = 8.0; 25.0 µL). Glycopeptide formation and glycosite occupancy were analyzed on an Orbitrap Fusion[™] Tribrid[™] Mass Spectrometer (Thermo) coupled to a Dionex Ultimate 3000 HPLC with an EASY-Spray[™] LC (100 Å C18 column length 150 mm, I.D. 75 μ m). The samples were eluted at 0.3 μ L/min using a 90-min gradient and a 185-min instrument method. Solvent A was 0.1% formic acid in water, and solvent B was 0.1% formic acid in acetonitrile. The gradient profile varied by peptide. The instrument method used an MS1 resolution of 60,000 at FWHM of 400 m/z, an automatic gain control (AGC) target of 3e5, and a mass range from 300 to 1,500 m/z. Electron transfer dissociation (ETD) MS2 spectra were generated at top speed for 3 s. ETD parameters were as follows: calibrated charge dependent ETD times, 2e5 reagent target, and precursor AGC target of 1e4. Glycopeptides were manually sequenced using Xcalibur software (Thermo). Relative abundances were obtained by integrating under the extracted ion chromatograms (± 10 ppm).




Characterization of peptides glycosylated by GalNAc-T2.




GTT*PSPVPTTSTT*SAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 91.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4540 (+1.49 ppm).




G T T*P S PV P TT*STTS A P



GTT*PSPVPTT*STTSAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 92.6$ min.


MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4545 (+2.01 ppm).




GTT*PSPVPT*TSTTSAP.


Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 94.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4534 (+0.86 ppm).






G T T* PS PV P TTSTTS A P



GTT*PSPVPTTST(13-T)SAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 100.6$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4717 (+3.54 ppm).



HO

HO


OH

HN O≓

GTT*PSPVPT(13-T)STTSAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 102.7$ min.


MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4714 (+3.23 ppm).




GTT*PSPVP(13-T)TSTTSAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 105.2$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4710 (+2.83 ppm).




G (T T)* PLS PLV P T'TISITIT* SIA P




GTT*PSPVPTTSTT*SAP.

The mass spectrum for this peptide does not allow the unambiguous assignment of the glycosite to Thr2 or Thr3. However, this compound has the identical fragmentation pattern and retention time as the major product of WT-T2/1 with MUC5AC-3, indicating that the glycopeptides are likely identical and that the occupied glycosite is Thr3. Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with t_r = 91.0 min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4551 (+2.64 ppm).




GTTPSPVPT*TISTTAGAP



GTTPSPVPT*TSTT*SAP.


Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 93.6$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4528 (+0.23 ppm).



 $R = \frac{1}{2} \frac{1}{2} \frac{1}{2}$


G (T T)* PLS PV PTTSTTSTT*SA P



G(13-(TT))PSPVPTTSTT*SAP.


The glycosite cannot be unambiguously assigned, and either Thr2 or Thr3 (**13**-(TT)) is glycosylated by T2(I253A/L310A)/**13**. Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 100.4$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4715 (+3.34 ppm).






GTTPSPVPT*TSTT*SAP



GTTPSPVP(13-T)TSTT*SAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 105.2$ min.


MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4687 (+0.48 ppm).



PTTDSTT*PAPTTK.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:20, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 50.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₆₃H₁₀₇N₁₅O₂₈: 760.8705, found: 760.8708 (+0.39 ppm).



HO

HO


OH

HN = 0 O = 0 R = 0 R = 0 $H_2N-PTTDSTTPAPTTK-COOH$


PTTDST(13-T)PAPTTK.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:20, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 73.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₆₇H₁₁₁N₁₅O₂₈: 786.8862, found: 786.8867 (+0.70 ppm).




Characterization of peptides glycosylated by GalNAc-T1.



PTTDSTT*PAPTTK.


Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:20, 103:42, 104:98, 109:98, 110:3, 185:3 with $t_r = 59.0$ min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₆₃H₁₀₇N₁₅O₂₈: 760.8705, found: 760.8700 (-0.66 ppm).



 $R = \frac{1}{2}$


PITITIDISTT PLA PITITIK




PTTDST(13-T)PAPTTK.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:20, 103:42, 104:98, 109:98, 110:3, 185:3 with t_r = 80.0 min.


MS (ESI) m/z ([M+2H]²⁺) calcd for C₆₇H₁₁₁N₁₅O₂₈: 786.8862, found: 786.8859 (-0.32 ppm).



Characterization of peptides glycosylated by GalNAc-T10.




G T* T* PS PV PTTSTA P



GT*T*PSPVPTTSTTSAP.


Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with t_r = 93.4 min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₉H₁₃₂N₁₈O₃₆: 954.4526, found: 954.4554 (+2.95 ppm).



 $R = c^{3}$

G T* T* PIS PIV PITITISITITIS A P



G(13-T)T*PSPVPTTSTTSAP.

Product formation and glycosite occupancy were determined using ETD fragmentation on an Orbitrap FusionTM TribridTM Mass Spectrometer coupled to a Dionex Ultimate 3000 HPLC. The gradient profile was as follows (min/%B): 0:3, 3:5, 93:25, 103:42, 104:98, 109:98, 110:3, 185:3 with t_r = 93.4 min.

MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₃H₁₃₆N₁₈O₃₆: 980.4682, found: 980.4716 (+3.44 ppm).

VII. Preparation of GalNAc-Ts (Table S2; Figure S7)

Secretion design

Soluble human GalNAc-T2 was generated by removing the N-terminal transmembrane domain and referencing published truncations.^{6,7} For GalNAc-T1 and -T10 secretion constructs, N-terminal truncations were made by cleaving at the middle or end of the stem region that follows the transmembrane domain, as identified by online protein secondary structure predictors GlobPlot (2.3) and HMMTOP (2.0), and published truncations were also referenced for GalNAc-T1 and -T10.^{1,7–9}

Cloning of truncated GalNAc-Ts.

Full length human GalNAc-T2 (EBI accession number LC043140.1) in the plasmid pCMV-NTAP was a kind gift from Lawrence Tabak (National Institutes of Health, Bethesda, MD). A truncated version (aa E43-N571) was cloned into p3xFLAG-CMV-8 using primers (GalNAc-T2 coding sequence underlined)

GACAAGCTTGCGGCCGCG<u>GAGGACTGGAATGAAATTG</u> (fwd) and CGATGAATTC<u>CTACTGCTGCAGGTTGAGC</u> (rev) and a NotI/EcoRI restriction strategy. As the presence of a 3xFLAG tag in the secretion construct prevented elution from FLAG[®] affinity resin, truncated GalNAc-T2 was sub-cloned into pFLAG-myc-CMV-19 using a NotI/EcoRI restriction strategy that excluded the myc tag from the coding sequence. This construct contains an N-terminal preprotrypsin leader sequence and an ampicillin resistance cassette.

Secretion constructs for GalNAc-T1 (NCBI Genbank[®] accession number X85018, aa D35-F559) and GalNAc-T10 (NCBI Genbank[®] accession number AJ505950, aa P40-N603) were assembled by Golden Gate cloning using the gBlocks depicted in Table S2. BsaI restriction sites at the joint regions of each gBlock enabled assembly. Silent mutations were included to mask endogenous BsaI sites.

The Golden Gate reaction was carried out using 20 fmol of each gBlock and 2000 U T4 DNA ligase in 15 μ L T4 DNA ligase buffer, using 25 cycles of 37 °C (2 min), 16 °C (5 min); 60 °C (10 min); 80 °C (20 min); and 4 °C (hold). Following assembly, BsaI sites were introduced into the flanking regions of the T1 gene by PCR using the primers CACACCAGGTCTCA<u>GGCCGCGGATGAAAAAAAGGAAGAGAGAGACTT</u> (fwd) and CACACCAGGTCTCT<u>AATTCTCAGAATATTTCTGGAAGGGTGACGT (rev)</u>. Amplicons were digested with BsaI to give NotI and EcoRI overhangs, and cloned into pFLAG-myc-CMV-19 while excluding the myc tag from the coding sequence.

Generation of GalNAc-T mutants.

Point mutations were introduced into wild-type GalNAc-T2 (WT-T2) and WT-T1 by site-directed mutagenesis using a strategy according to a literature procedure.¹⁰ The primer pairs used to generate GalNAc-T2 mutants (mismatch underlined) were CACCCATCGCCGATGTCATTAATATGGACAAC (fwd) and GACATCGGCGATGGGTGACACAACCCGAGTC (rev) for T2(I253A), GCTGGTGGGGCCTTTGTGATGGATAAGTTC (fwd) and CATCACAAAGGCCCCACCAGCAATCATGGGG (rev) for T2(L310A), GGACACGTGGCCCGGAAGCAGCACCCCTACACGTTC (fwd) and GCTTCCGGGCCACGTGTCCCACACGGCTGCAC (rev) for T2(F361A), and GACACGTGTCCCGGAAGCAGCAC (fwd) and CTTCCGGGACACGTGTCCCAC (rev) for T2(F361S). The F361 mutants were generated from full-length GalNAc-T2 in pCMV-NTAP, and truncated versions were cloned and sub-cloned as described for the wild-type enzyme in the previous section. Primer pairs for GalNAc-T1 mutants (mismatch underlined) were CCATCGCCGATGTGATCAGTGATGATAC (fwd) and ACATCGGCGATGGGACACACC (rev) for T1(I238A), and GAGGCGCCTTTTCAATAGACAGAGATTACTTTC (fwd) and GAAAAGGCGCCTCCTGCCATGG (rev) for T1(L295A). The GalNAc-T10 double


mutant was assembled using a modified gBlock during Golden Gate assembly (Table S2).

Protein expression.

Truncated GalNAc-Ts were expressed in HEK-293T cells and purified by FLAG affinity chromatography. Briefly, cells were grown in Dulbecco's Modified Eagle Medium with 10% (v/v) fetal bovine serum in 15-cm dishes and transfected with expression plasmids using TransIT[®]-293 according to the manufacturer's instructions and using 37.5 µg plasmid DNA per dish. The medium was changed after 24 h, and protein expression was allowed to continue for another 24 h. The supernatant was collected and centrifuged for 15 min at 3650 x g at 4 °C. The clarified supernatant was treated with cOmpleteTM mini EDTA-free protease inhibitor and loaded on a column packed with anti-FLAG[®] M2 agarose resin (1.25 mL) pre-conditioned according to the manufacturer's instructions. The resin was washed with Tris buffered saline (TBS, 25 mM Tris-HCl, 150 mM NaCl, pH = 7.4; 2 x 10 mL). Protein was eluted by $3xFLAG^{\mathbb{R}}$ peptide (100 µg/mL) in TBS (25 mM Tris-HCl, 150 mM NaCl, pH = 7.4; 5 mL). Glycerol was added to the pooled elution fractions to a final concentration of 25% (v/v). Proteins were aliquoted and stored at -80 °C. Protein quantification was performed by densitometric analysis of bands on SDS-PAGE gels stained with Colloidal Blue Staining Kit and comparison to known standards of human serum albumin (Figure S7A). Immunodecoration after Western blot was performed using a murine anti-FLAG[®] antibody (Figure S7B).


VIII. Characterization of Chromophore-Labeled Peptides (Figure 2A)

Peptide-1. The peptide was purified by preparative HPLC on C-18 silica gel ($20 \rightarrow 60\%$ acetonitrile/water; 0.1% trifluoroacetic acid). MS (ESI) *m/z* ([M+2H]²⁺) calcd for C₆₃H₉₇N₂₁O₂₃: 757.8533, found: 757.8524 (-1.20 ppm).



Peptide-2. The peptide was purified by preparative HPLC on C-18 silica gel $(30 \rightarrow 40\%$ acetonitrile/water; 0.1% trifluoroacetic acid).


MS (ESI) m/z ([M+2H]²⁺) calcd for C₇₄H₁₀₅N₂₁O₂₃: 827.8846, found: 827.8828 (-2.19 ppm).




Peptide-3. The peptide containing a protected sugar was purified by preparative HPLC on C-18 silica gel $(30\rightarrow40\%$ acetonitrile/water). The title compound was purified by preparative HPLC on C-18 silica gel $(5\rightarrow50\%$ acetonitrile/water; 0.1% trifluoroacetic acid).

MS (ESI) m/z ([M+2H]²⁺) calcd for C₈₀H₁₂₇N₂₁O₃₆: 978.9376, found: 978.9376 (-0.03 ppm).

IX. Preparation of UDP-Sugars (Figures 2B and 2C)



Methylhex-5-ynoic acid. LDA was prepared by the dropwise addition of *n*-BuLi (2.5 M in hexanes; 14.2 mL, 36 mmol) to a solution of *i*-Pr₂NH (6.43 mL, 45.9 mmol) in THF (24.0 mL) in a 250-mL round-bottom flask at -78 °C. The reaction mixture was stirred at 0 °C for 15 min, and then it was cooled to -20 °C. A solution of propanoic acid (1.33 mL, 17.8 mmol) in HMPA (3.00 mL) was added dropwise over 10 min to the LDA solution at -20 °C. The mixture was stirred at r.t. for 30 min, and then it was cooled to 0 °C. Next, a solution of (4-bromobut-1-yn-1-yl)trimethylsilane¹¹ (3.04 g, 14.8 mmol) in THF (5.90 mL) was added. The resulting mixture was allowed to warm to r.t., and it was stirred for 2 h. The reaction was quenched by the addition of water (100 mL). The aqueous layer was rinsed with ethyl acetate (50 mL), acidified using HCl (2 M), and extracted with ethyl acetate (3 x 50 mL). The extracted organic layers were combined, dried over Na₂SO₄, and concentrated. The acid was used without further purification.



(*R*)-*N*-((*R*)-2-Hydroxy-1-phenylethyl)-2-methylhex-5-ynamide. The title compound was prepared from (*R*)-2-amino-2-phenylethan-1-ol (1.37 g, 10.0 mmol) and methylhex-5-ynoic acid (1.26 g, 10.0 mmol) according to a literature procedure.¹² The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes)


and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water; 0.1% trifluoroacetic acid): 495 mg (21% over two steps). White solid.

¹H NMR (500 MHz, CDCl₃) δ 7.37–7.32 (m, 2H), 7.31–7.25 (m, 3H), 6.41 (d, J = 6.8 Hz, 1H), 5.05 (ddd, J = 7.0, 5.1, 5.1 Hz, 1H), 3.84 (d, J = 5.1 Hz, 2H), 3.08 (br s, 1H), 2.55–2.46 (m, 1H), 2.33–2.20 (m, 2H), 2.00 (t, J = 2.6 Hz, 1H), 1.91–1.82 (m, 1H), 1.65–1.56 (m, 1H), 1.14 (d, J = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 176.5, 139.2, 128.7, 127.6, 126.6, 83.8, 69.3, 66.1, 55.6, 39.8, 32.3, 17.6, 16.4.

FT-IR (neat) 3295, 3071, 3031, 2937, 2877, 1640, 1545, 1491, 1451, 1390, 1371, 1280, 1245, 1200, 1179, 1116, 1087, 1072, 1042, 1002, 939, 882, 841, 749, 697, 636, 614, 561, 524, 500 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₁₅H₁₉NNaO₂: 268.1313, found: 268.1309. $R_f = 0.38$ (60% ethyl acetate/hexanes).



(*S*)-*N*-((*R*)-2-Hydroxy-1-phenylethyl)-2-methylhex-5-ynamide. The title compound was prepared from (*R*)-2-amino-2-phenylethan-1-ol (1.37 g, 10.0 mmol) and methylhex-5-ynoic acid (1.26 g, 10.0 mmol) according to a literature procedure.¹² The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water; 0.1% trifluoroacetic acid): 469 mg (19% over two steps). White solid.

¹H NMR (500 MHz, CDCl₃) δ 7.38–7.33 (m, 2H), 7.32–7.27 (m, 3H), 6.43 (d, J = 7.4 Hz, 1H), 5.06 (ddd, J = 7.0, 5.0, 5.0 Hz, 1H), 3.89–3.80 (m, 2H), 2.82 (br s, 1H), 2.58–2.50 (m, 1H), 2.21 (dddd, J = 17.1, 6.1, 6.1, 2.6 Hz, 1H), 2.08 (dddd, J = 17.7, 8.9, 6.3, 2.7 Hz, 1H), 1.97 (t, J = 2.6 Hz, 1H), 1.86–1.78 (m, 1H), 1.62–1.53 (m, 1H), 1.19 (d, J = 6.8 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 176.5, 139.4, 128.8, 127.8, 126.7, 83.7, 69.4, 66.2, 55.6, 39.8, 32.5, 17.8, 16.5.

FT-IR (neat) 3271, 3069, 3033, 2966, 2947, 2928, 2876, 1642, 1538, 1492, 1472, 1453, 1385, 1367, 1347, 1292, 1270, 1252, 1218, 1195, 1184, 1115, 1095, 1067, 1046, 1002, 941, 910, 899, 882, 839, 753, 696, 679, 644, 556, 529, 502, 441 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₁₅H₁₉NNaO₂: 268.1313, found: 268.1308. $R_f = 0.26$ (60% ethyl acetate/hexanes).


n-Bu ↓ COOH

Me

Assignment of absolute stereochemistry of (*S*)-2-methylhexanoic acid [49642-51-5]. A mixture of *N*-((*R*)-2-Hydroxy-1-phenylethyl)-2-methylhex-5-ynamide (80.0 mg, 0.326 mmol; $R_f = 0.26$ (60% ethyl acetate/hexanes)) and Pd/C (10 wt%; 14.8 mg) in MeOH (6.0 mL) in a 25-mL round-bottom flask was stirred under atmospheric pressure of H₂ at r.t. for 12 h, and then the reaction mixture was filtered through a pad of Celite[®] and concentrated. The compound was hydrolyzed to obtain 2-methylhexanoic acid according


to a literature procedure.¹² The product was purified by column chromatography (10% \rightarrow 78% diethyl ether/pentane): 39.8 mg (94% over two steps). Colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 2.45 (h, *J* = 7.0 Hz, 1H), 1.73–1.64 (m, 1H), 1.48–1.38 (m, 1H), 1.36–1.27 (m, 4H), 1.17 (d, *J* = 6.9 Hz, 3H), 0.89 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 183.9, 39.6, 33.4, 29.4, 22.7, 17.0, 14.1. [α]²³_D = +18.1° (c = 1.02, CHCl₃).

The absolute stereochemistry was assigned as (*S*) by comparison with reported optical rotations (lit.¹³ $[\alpha]_D^{20} = +20.6^\circ$ (c = 0.5, CHCl₃; *S* enantiomer); lit.¹⁴ $[\alpha]_D^{20} = +18.1^\circ$ (c = 0.84, CHCl₃; *S* enantiomer)).



Representative experimental procedure for the preparation of peracetylated *N*-acetyl-β-D-galactosamine derivatives (Route 1).

1,3,4,6-Tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride¹⁵ and azido acids¹⁶ were prepared according to literature procedures. A mixture of the sugar (192 mg, 0.500 mmol), the acid (0.500 mmol), and Hünig's base (0.261 mL, 1.50 mmol) in DMF (4.00 mL) in a 25-mL round-bottom flask was cooled to 0 °C. COMU[®] was added, and the reaction mixture was stirred at 0 °C for 1 h. The solution was allowed to warm to r.t. and stirred for 3 h. The mixture was diluted by the addition of ethyl acetate (50 mL), rinsed with HCl (1 M; 2 x 10 mL), saturated aqueous NaHCO₃ (2 x 10 mL), and brine (20 mL), dried over Na₂SO₄, and concentrated. The product was purified by column chromatography.




1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-2-azidopropanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (384 mg, 1.00 mmol) and (*S*)-2-azidopropanoic acid (115 mg, 1.00 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 397 mg (89%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.77 (d, J = 9.5 Hz, 1H), 5.76 (d, J = 8.7 Hz, 1H), 5.30 (d, J = 3.3 Hz, 1H), 5.20 (dd, J = 11.3, 3.4 Hz, 1H), 4.27 (ddd, J = 11.3, 9.1, 9.1 Hz, 1H), 4.09–3.99 (m, 3H), 3.90 (q, J = 7.0 Hz, 1H), 2.06 (s, 3H), 2.01 (s, 3H), 1.94 (s, 3H), 1.90 (s, 3H), 1.32 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 170.5, 170.4, 170.2, 169.3, 92.5, 71.7, 69.7, 66.4, 61.5, 59.1, 49.6, 20.6, 20.5, 20.5, 20.4, 17.1.

FT-IR (neat) 3337, 2975, 2956, 2934, 2109, 1745, 1665, 1530, 1435, 1369, 1321, 1268, 1215, 1162, 1151, 1068, 1036, 972, 946, 915, 903, 731, 703, 668, 645, 628, 601, 556, 539, 495, 480 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₁₇H₂₄N₄NaO₁₀: 467.1390, found: 467.1383.




1,3,4,6-Tetra-*O***-acetyl-2-((***R***)-2-azidopropanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (576 mg, 1.50 mmol) and (*R*)-2-azidopropanoic acid (173 mg, 1.50 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 458 mg (69%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.59 (d, J = 9.5 Hz, 1H), 5.81 (d, J = 8.8 Hz, 1H), 5.36 (d, J = 3.1 Hz, 1H), 5.22 (dd, J = 11.2, 3.3 Hz, 1H), 4.35 (ddd, J = 11.2, 9.2, 9.2 Hz, 1H), 4.15–4.05 (m, 3H), 3.98 (q, J = 7.0 Hz, 1H), 2.14 (s, 3H), 2.09 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.41 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 170.6, 170.5, 170.3, 169.5, 92.5, 71.9, 70.2, 66.5, 61.5, 59.2, 49.9, 20.9, 20.7, 20.6, 17.2.

FT-IR (neat) 3311, 2983, 2940, 2110, 1743, 1685, 1531, 1434, 1368, 1212, 1161, 1116, 1069, 1039, 955, 917, 904, 865, 733, 647, 601, 561, 537 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₁₇H₂₄N₄NaO₁₀: 467.1390, found: 467.1381.




1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-2-azidobutanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (544 mg, 1.42 mmol) and (*S*)-2-azidobutanoic acid (183 mg, 1.42 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 435 mg (67%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.49 (d, J = 9.4 Hz, 1H), 5.78 (d, J = 8.8 Hz, 1H), 5.39 (dd, J = 3.3, 0.7 Hz, 1H), 5.21 (dd, J = 11.3, 3.3 Hz, 1H), 4.38 (ddd, J = 11.3, 9.1, 9.1 Hz, 1H), 4.17–4.10 (m, 2H), 4.09–4.04 (m, 1H), 3.91 (dd, J = 6.6, 4.9 Hz, 1H), 2.15 (s, 3H), 2.09 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.90–1.74 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 170.6, 170.6, 170.3, 167.0, 169.4, 92.6, 71.9, 70.1, 66.4, 65.5, 61.4, 49.8, 25.3, 20.9, 20.8, 20.7, 9.4.

FT-IR (neat) 3319, 2973, 2941, 2881, 2104, 1745, 1669, 1532, 1435, 1368, 1214, 1162, 1116, 1071, 1040, 941, 899, 736, 648, 601, 561, 538 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₀: 481.1547, found: 481.1535.




1,3,4,6-Tetra-*O***-acetyl-2-((***R***)-2-azidobutanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (518 mg, 1.35 mmol) and (*R*)-2-azidobutanoic acid (174 mg, 1.35 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 417 mg (68%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.47 (d, J = 9.5 Hz, 1H), 5.80 (d, J = 8.8 Hz, 1H), 5.38 (dd, J = 3.3, 0.7 Hz, 1H), 5.19 (dd, J = 11.3, 3.3 Hz, 1H), 4.40 (ddd, J = 11.3, 9.2, 9.2 Hz, 1H), 4.18–4.11 (m, 2H), 4.07–4.05 (m, 1H), 3.94 (dd, J = 6.2, 5.0 Hz, 1H), 2.16 (s, 3H), 2.11 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H), 1.91–1.78 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 170.6, 170.5, 170.3, 169.8, 169.5, 92.6, 71.9, 70.2, 66.4, 65.3, 61.4, 49.8, 25.2, 21.0, 20.8, 20.7, 9.3.

FT-IR (neat) 3317, 2973, 2937, 2881, 2104, 1746, 1671, 1532, 1435, 1368, 1215, 1161, 1117, 1071, 1041, 937, 901, 863, 736, 676, 630, 601, 561, 537 cm⁻¹.


HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₀: 481.1547, found: 481.1550.



1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-2-azido-3-phenylpropanamido)-2-deoxy-β-D**galactopyranose. The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2amino-2-deoxy-β-D-galactopyranose hydrochloride (384 mg, 1.00 mmol) and (*S*)-2azido-3-phenylpropanoic acid (191 mg, 1.00 mmol). The product was purified by column chromatography (1%→10% acetone/CH₂Cl₂): 456 mg (88%). White solid. ¹H NMR (500 MHz, CDCl₃) δ 7.32–7.29 (m, 2H), 7.28–7.25 (m, 1H), 7.25–7.22 (m, 2H), 6.48 (d, *J* = 9.3 Hz, 1H), 5.79 (d, *J* = 8.8 Hz, 1H), 5.39 (dd, *J* = 3.2, 0.7 Hz, 1H), 5.21 (dd, *J* = 11.3, 3.3 Hz, 1H), 4.37 (ddd, *J* = 11.3, 9.0, 9.0 Hz, 1H), 4.18–4.05 (m, 4H), 3.27 (dd, *J* = 14.0, 4.3 Hz, 1H), 2.81 (dd, *J* = 14.1, 9.1 Hz, 1H), 2.17 (s, 3H), 2.10 (s, 3H), 2.03 (s, 3H), 1.97 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.6, 170.6, 170.3, 169.5, 169.5, 136.1, 129.4, 128.9, 127.4, 92.7, 71.9, 70.0, 66.4, 65.9, 61.4, 50.2, 38.6, 21.0, 20.8, 20.7. FT-IR (neat) 3327, 3084, 3065, 3031, 2929, 2110, 1745, 1675, 1531, 1498, 1454, 1433, 1368, 1301, 1216, 1162, 1115, 1073, 1040, 947, 913, 733, 702, 595, 556, 538 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₃H₂₈N₄NaO₁₀: 543.1703, found: 543.1696.




1,3,4,6-Tetra-*O***-acetyl-2-(**(*R***)-2-azido-3-phenylpropanamido)-2-deoxy-β-Dgalactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2amino-2-deoxy-β-D-galactopyranose hydrochloride (192 mg, 0.50 mmol) and (*R*)-2azido-3-phenylpropanoic acid (95.6 mg, 0.50 mmol). The product was purified by column chromatography (1%→10% acetone/CH₂Cl₂): 136 mg (52%). White solid. ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.26 (m, 3H), 7.26–7.22 (m, 2H), 6.36 (d, *J* = 9.3 Hz, 1H), 5.80 (d, *J* = 8.8 Hz, 1H), 5.39 (dd, *J* = 3.2, 0.7 Hz, 1H), 5.20 (dd, *J* = 11.3, 3.4 Hz, 1H), 4.34 (ddd, *J* = 11.3, 9.1, 9.1 Hz, 1H), 4.19–4.09 (m, 3H), 4.05 (ddd, *J* = 6.5, 6.5, 1.0 Hz, 1H), 3.30 (dd, *J* = 14.1, 4.2 Hz, 1H), 2.82 (dd, *J* = 14.1, 9.0 Hz, 1H), 2.18 (s, 3H), 2.10 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 170.5, 170.3, 169.4, 169.4, 136.1, 129.5, 128.9, 127.5,

92.6, 72.0, 70.1, 66.4, 65.8, 61.4, 50.2, 38.6, 21.0, 20.8, 20.8, 20.7.

FT-IR (neat) 3327, 2952, 2924, 2854, 2113, 1746, 1685, 1532, 1455, 1435, 1368, 1300, 1217, 1160, 1117, 1074, 1041, 949, 919, 908, 735, 702, 601 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₃H₂₈N₄NaO₁₀: 543.1703, found: 543.1706.




1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-2-azido-3-methoxypropanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (510 mg, 1.33 mmol) and (*S*)-2-azido-3-methoxypropanoic acid (193 mg, 1.33 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 453 mg (72%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.44 (d, J = 9.5 Hz, 1H), 5.78 (d, J = 8.7 Hz, 1H), 5.40 (dd, J = 3.2, 0.7 Hz, 1H), 5.18 (dd, J = 11.3, 3.3 Hz, 1H), 4.36 (ddd, J = 11.3, 9.1, 9.1 Hz, 1H), 4.19–4.09 (m, 3H), 4.04 (ddd, J = 6.5, 6.5, 0.8 Hz, 1H), 3.80–3.69 (m, 2H), 3.38 (s, 3H), 2.17 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.5, 170.5, 170.2, 169.3, 167.9, 92.7, 72.4, 72.0, 69.9, 66.4, 63.3, 61.4, 59.4, 50.1, 20.9, 20.8, 20.8, 20.7.

FT-IR (neat) 3337, 2957, 2921, 2852, 2109, 1747, 1675, 1534, 1457, 1435, 1369, 1305, 1219, 1162, 1116, 1073, 1041, 950, 923, 900, 849, 800, 602, 562 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₁: 497.1496, found: 497.1485.




1,3,4,6-Tetra-*O***-acetyl-2-((***R***)-2-azido-3-methoxypropanamido)-2-deoxy-\beta-D-galactopyranose. The title compound was prepared from 1,3,4,6-tetra-***O***-acetyl-2-amino-2-deoxy-\beta-D-galactopyranose hydrochloride (510 mg, 1.33 mmol) and (***R***)-2-azido-3-methoxypropanoic acid (193 mg, 1.33 mmol). The product was purified by column chromatography (15%\rightarrow100% ethyl acetate/hexanes): 459 mg (73%). White solid.**

¹H NMR (500 MHz, CDCl₃) δ 6.43 (d, J = 9.4 Hz, 1H), 5.78 (d, J = 8.8 Hz, 1H), 5.39 (dd, J = 3.3, 0.6 Hz, 1H), 5.19 (dd, J = 11.3, 3.3 Hz, 1H), 4.37 (ddd, J = 11.2, 9.1, 9.1 Hz, 1H), 4.19–4.09 (m, 3H), 4.04 (ddd, J = 6.6, 6.6, 0.9 Hz, 1H), 3.81–3.65 (m, 2H), 3.37 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.5, 170.4, 170.2, 169.4, 167.9, 92.6, 72.4, 72.1, 70.1, 66.4, 63.1, 61.3, 59.4, 50.1, 21.0, 20.8, 20.7.

FT-IR (neat) 3340, 2952, 2921, 2850, 2108, 1746, 1688, 1533, 1457, 1436, 1369, 1218, 1162, 1115, 1072, 1041, 955, 925, 901, 847, 803, 600, 557 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₁: 497.1496, found: 497.1493.




1,3,4,6-Tetra-O-acetyl-2-((R)-3-azido-2-methylpropanamido)-2-deoxy-\beta-D-galactopyranose. The title compound was prepared from 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (384 mg, 1.00 mmol) and (R)-3-azido-2-methylpropanoic acid¹⁷ (129 mg, 1.00 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 318 mg (69%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.08 (d, J = 9.5 Hz, 1H), 5.76 (d, J = 8.8 Hz, 1H), 5.35 (d, J = 2.8 Hz, 1H), 5.15 (dd, J = 11.3, 3.4 Hz, 1H), 4.44 (ddd, J = 11.3, 9.2, 9.2 Hz, 1H), 4.16–4.03 (m, 3H), 3.48 (dd, J = 12.1, 9.1 Hz, 1H), 3.28 (dd, J = 12.1, 4.8 Hz, 1H), 2.39–2.32 (m, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 174.2, 170.7, 170.6, 170.3, 169.8, 92.7, 71.9, 70.3, 66.6, 61.6, 53.9, 49.6, 41.4, 20.8, 20.8, 20.6, 15.4.

FT-IR (neat) 3317, 2974, 2937, 2102, 1747, 1665, 1545, 1439, 1369, 1218, 1161, 1118, 1071, 1041, 952, 923, 900, 596 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₀: 481.1547, found: 481.1538.




1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-3-azido-2-methylpropanamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (384 mg, 1.00 mmol) and (*S*)-3-azido-2-methylpropanoic acid¹⁴ (129 mg, 1.00 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 328 mg (72%). Light-yellow solid.

¹H NMR (500 MHz, CDCl₃) δ 5.75 (d, J = 8.8 Hz, 1H), 5.74 (d, J = 9.4 Hz, 1H), 5.38 (dd, J = 3.4, 1.1 Hz, 1H), 5.14 (dd, J = 11.3, 3.3 Hz, 1H), 4.47 (ddd, J = 11.3, 9.1, 9.1 Hz, 1H), 4.19–4.10 (m, 2H), 4.05 (ddd, J = 6.5, 6.5, 1.2 Hz, 1H), 3.51 (dd, J = 12.0, 9.2 Hz, 1H), 3.32 (dd, J = 12.0, 4.7 Hz, 1H), 2.39–2.30 (m, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 1.09 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 174.1, 171.0, 170.6, 170.3, 169.6, 93.1, 72.1, 70.1, 66.5, 61.5, 54.0, 49.9, 41.6, 20.9, 20.8, 20.6, 15.5.


FT-IR (neat) 3312, 2977, 2937, 2102, 1745, 1664, 1545, 1437, 1369, 1216, 1162, 1118, 1071, 1041, 953, 923, 899, 850, 629, 597, 559, 538, 488 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₁₈H₂₆N₄NaO₁₀: 481.1547, found: 481.1523.



1,3,4,6-Tetra-O-acetyl-2-((R)-2-methylpent-4-ynamido)-2-deoxy-β-D-

galactopyranose. (*R*)-2-Methylpent-4-ynoic acid was prepared according to a literature procedure.¹² The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy-β-D-galactopyranose hydrochloride (312 mg, 0.813 mmol) and (*R*)-2-methylpent-4-ynoic acid (91.0 mg, 0.812 mmol). The product was purified by column chromatography (1st purification: 8%→70% acetone/hexanes; 2nd purification: 12%→100% ethyl acetate/hexanes): 225 mg (63%). White solid. ¹H NMR (500 MHz, CDCl₃) δ 5.69 (d, *J* = 8.8 Hz, 1H), 5.49 (d, *J* = 9.6 Hz, 1H), 5.38 (dd, *J* = 3.3, 0.8 Hz, 1H), 5.10 (dd, *J* = 11.3, 3.3 Hz, 1H), 4.52 (ddd, *J* = 11.1, 9.3, 9.3 Hz, 1H), 4.18 (dd, *J* = 11.3, 6.7 Hz, 1H), 4.12 (dd, *J* = 11.3, 6.4 Hz, 1H), 4.02 (ddd, *J* = 6.5, 6.5, 1.0 Hz, 1H), 2.45–2.33 (m, 2H), 2.29 (ddd, *J* = 15.8, 4.9, 2.8 Hz, 1H), 2.17 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.98 (dd, *J* = 2.7, 2.7 Hz, 1H), 1.15 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 174.8, 170.8, 170.5, 170.3, 169.7, 93.1, 81.8, 72.0, 70.5, 70.4, 66.5, 61.4, 49.6, 41.0, 23.2, 21.2, 20.8, 20.8, 17.4. FT-IR (neat) 3291, 2968, 2919, 2852, 1747, 1663, 1543, 1457, 1432, 1369, 1220, 1162, 1114, 1070, 1042, 956, 923, 898, 710, 675, 659, 643, 630, 595, 536 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₀H₂₇NNaO₁₀: 464.1533, found: 464.1520.



1,3,4,6-Tetra-O-acetyl-2-((S)-2-methylpent-4-ynamido)-2-deoxy-β-D-


galactopyranose. (*S*)-2-Methylpent-4-ynoic acid was prepared according to a literature procedure.¹² The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (472 mg, 1.23 mmol) and (*S*)-2-methylpent-4-ynoic acid (138 mg, 1.23 mmol). The product was purified by column chromatography (1st purification: 12% \rightarrow 100% ethyl acetate/hexanes; 2nd purification: 8% \rightarrow 70% acetone/hexanes): 322 mg (59%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 5.72 (d, J = 8.8 Hz, 1H), 5.52 (d, J = 9.5 Hz, 1H), 5.38 (dd, J = 3.3, 0.7 Hz, 1H), 5.08 (dd, J = 11.3, 3.3 Hz, 1H), 4.51 (ddd, J = 11.4, 9.2, 9.2 Hz, 1H), 4.18 (dd, J = 11.4, 6.7 Hz, 1H), 4.12 (dd, J = 11.3, 6.5 Hz, 1H), 4.02 (ddd, J = 6.5, 6.5, 1.2 Hz, 1H), 2.45–2.29 (m, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.98 (dd, J = 2.6, 2.6 Hz, 1H), 1.16 (d, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 174.8, 170.8, 170.5, 170.3, 169.6, 93.1, 81.8, 72.1, 70.4, 70.4, 66.4, 61.4, 49.6, 40.8, 23.1, 21.0, 20.9, 20.8, 17.4.

FT-IR (neat) 3294, 2967, 2918, 2851, 1748, 1665, 1542, 1458, 1431, 1370, 1221, 1162, 1115, 1073, 1042, 953, 921, 904, 674, 657, 642, 621, 596, 562, 553, 539 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₀H₂₇NNaO₁₀: 464.1533, found: 464.1524.




1,3,4,6-Tetra-O-acetyl-2-((R)-2-methylhex-5-ynamido)-2-deoxy-β-D-

galactopyranose. The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2amino-2-deoxy- β -D-galactopyranose hydrochloride (255 mg, 0.664 mmol) and (*R*)-2methylhex-5-ynoic acid (83.7 mg, 0.663 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 208 mg (69%). White solid. ¹H NMR (500 MHz, CDCl₃) δ 5.73 (d, J = 8.8 Hz, 1H), 5.47 (d, J = 9.6 Hz, 1H), 5.38 (dd, J = 3.2, 0.6 Hz, 1H), 5.12 (dd, J = 11.2, 3.3 Hz, 1H), 4.49 (ddd, J = 11.4, 9.3, 9.3 Hz, 1H), 4.17 (dd, J = 11.3, 6.7 Hz, 1H), 4.11 (dd, J = 11.3, 6.5 Hz, 1H), 4.03 (ddd, J = 6.5, 6.5, 0.9 Hz, 1H), 2.43–2.36 (m, 1H), 2.26–2.05 (m, 2H), 2.17 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.95 (dd, J = 2.7, 2.7 Hz, 1H), 1.83–1.76 (m, 1H), 1.57–1.50 (m, 1H), 1.09 (d, J = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 176.0, 170.8, 170.6, 170.3, 169.5, 92.8, 83.3, 72.1, 70.6, 69.6, 66.6, 61.4, 49.4, 40.1, 32.0, 21.0, 20.8, 20.7, 18.0, 16.3.

FT-IR (neat) 3285, 3081, 2967, 2936, 1746, 1660, 1541, 1434, 1369, 1217, 1161, 1118, 1070, 1041, 956, 928, 902, 736, 648, 597, 538 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₁H₂₉NNaO₁₀: 478.1689, found: 478.1682.




1,3,4,6-Tetra-*O***-acetyl-2-((***S***)-2-methylhex-5-ynamido)-2-deoxy-\beta-D-galactopyranose.** The title compound was prepared from 1,3,4,6-tetra-*O*-acetyl-2-amino-2-deoxy- β -D-galactopyranose hydrochloride (265 mg, 0.690 mmol) and (*S*)-2-methylhex-5-ynoic acid (87.1 mg, 0.690 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 229 mg (73%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 5.73 (d, J = 8.8 Hz, 1H), 5.49 (d, J = 9.5 Hz, 1H), 5.39 (dd, J = 3.2, 0.8 Hz, 1H), 5.08 (dd, J = 11.5, 3.3 Hz, 1H), 4.49 (ddd, J = 11.5, 9.2, 9.2 Hz, 1H), 4.18 (dd, J = 11.4, 6.6 Hz, 1H), 4.12 (dd, J = 11.4, 6.5 Hz, 1H), 4.03 (ddd, J = 6.5, 6.5, 1.2 Hz, 1H), 2.44–2.36 (m, 1H), 2.25–2.19 (m, 1H), 2.17 (s, 3H), 2.11 (s, 3H), 2.11–2.06 (m, 1H), 2.05 (s, 3H), 2.02 (s, 3H), 1.95 (dd, J = 2.7, 2.7 Hz, 1H), 1.82–1.75 (m, 1H), 1.57–1.50 (m, 1H), 1.09 (d, J = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 176.1, 170.7, 170.5, 170.3, 169.6, 93.3, 83.3, 72.1, 70.3, 69.6, 66.4, 61.5, 49.3, 40.2, 32.0, 20.9, 20.8, 20.8, 18.0, 16.4.


FT-IR (neat) 3287, 2966, 2932, 1745, 1661, 1540, 1434, 1369, 1216, 1162, 1118, 1069, 1040, 957, 920, 902, 733, 647, 597, 537 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₁H₂₉NNaO₁₀: 478.1689, found: 478.1689.



Preparation of tri-*O*-acetylated *N*-acetyl-α-D-galactosamine 1-diallyl phosphates (Route 1).

The 1-*O*-acetyl group was deprotected according to a literature procedure,¹⁸ and the crude product was used for the next step without further purification. These compounds were prepared according to a literature procedure.¹⁹




Diallyl 3,4,6-tri-*O***-acetyl-2-((***S***)-2-azidopropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*S*)-2-azidopropanamido)-2-deoxy- β -D-galactopyranose (748 mg, 1.86 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 701 mg (67%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 7.01 (d, J = 9.0 Hz, 1H), 5.90–5.81 (m, 2H), 5.65 (dd, J = 6.3, 3.3 Hz, 1H), 5.39 (dd, J = 3.2, 1.3 Hz, 1H), 5.32–5.26 (m, 2H), 5.22–5.18 (m, 2H), 5.15 (dd, J = 11.5, 3.2 Hz, 1H), 4.54–4.47 (m, 5H), 4.39 (ddd, J = 6.4, 6.4, 0.8 Hz, 1H), 4.07–3.99 (m, 2H), 3.89 (q, J = 7.0 Hz, 1H), 2.07 (s, 3H), 1.94 (s, 3H), 1.89 (s, 3H), 1.39 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.9, 170.4, 170.2, 170.0, 132.0 (d, *J* = 6.9 Hz), 131.9 (d, *J* = 6.7 Hz), 118.8, 118.7, 96.4 (d, *J* = 6.7 Hz), 68.6 (d, *J* = 3.7 Hz), 68.5, 67.1, 66.7, 61.4, 58.5, 47.6 (d, *J* = 7.7 Hz), 20.5, 20.5, 17.1.

³¹P NMR (202 MHz, CDCl₃) δ –2.1.

FT-IR (neat) 3270, 3079, 2983, 2114, 1745, 1690, 1529, 1454, 1427, 1371, 1217, 1164, 1137, 1103, 1052, 1018, 990, 945, 675, 647, 626, 601, 558, 531, 474 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₁H₃₁N₄NaO₁₂P: 585.1574, found: 585.1571.



Diallyl 3,4,6-tri-O-acetyl-2-((R)-2-azidopropanamido)-2-deoxy-α-D-

galactopyranosyl-1-phosphate. The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azidopropanamido)-2-deoxy- β -D-galactopyranose (277 mg, 0.688 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 132 mg (34%). White solid.


¹H NMR (500 MHz, CDCl₃) δ 6.51 (d, J = 9.5 Hz, 1H), 6.00–5.90 (m, 2H), 5.76 (dd, J = 6.0, 3.4 Hz, 1H), 5.45 (dd, J = 3.3, 1.3 Hz, 1H), 5.43–5.37 (m, 2H), 5.33–5.28 (m, 2H), 5.23 (dd, J = 11.4, 3.2 Hz, 1H), 4.65–4.57 (m, 5H), 4.42 (ddd, J = 6.5, 6.5, 1.4 Hz, 1H),

4.15–4.06 (m, 2H), 4.04 (q, *J* = 7.1 Hz, 1H), 2.16 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.49 (d, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 170.4, 170.2, 132.1 (d, *J* = 6.7 Hz), 119.2, 119.0, 96.5 (d, *J* = 6.1 Hz), 69.0 (d, *J* = 5.3 Hz), 68.9, 68.8 (d, *J* = 5.3 Hz), 67.5, 66.9, 61.5, 59.0, 47.8 (d, *J* = 7.8 Hz), 20.8, 20.8, 20.7, 17.1.

³¹P NMR (202 MHz, CDCl₃) δ –1.4.

FT-IR (neat) 3268, 3083, 2959, 2928, 2854, 2112, 1749, 1691, 1534, 1457, 1427, 1372, 1235, 1164, 1138, 1102, 1052, 1024, 992, 949, 893, 875, 650, 625, 598, 536, 473 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₁H₃₁N₄NaO₁₂P: 585.1574, found: 585.1571.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***S***)-2-azidobutanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*S*)-2azidobutanamido)-2-deoxy- β -D-galactopyranose (275 mg, 0.660 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 124 mg (33%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 7.20 (d, J = 9.0 Hz, 1H), 5.90–5.82 (m, 2H), 5.64 (dd, J = 6.3, 3.3 Hz, 1H), 5.40 (dd, J = 3.2, 1.3 Hz, 1H), 5.32–5.27 (m, 2H), 5.23–5.19 (m, 2H), 5.16 (dd, J = 11.6, 3.1 Hz, 1H), 4.56 (dddd, J = 12.0, 9.1, 3.2, 3.2 Hz, 1H), 4.53–4.46 (m, 4H), 4.42 (ddd, J = 6.5, 6.5, 1.3 Hz, 1H), 4.78–4.01 (m, 2H), 3.68 (dd, J = 7.3, 5.7 Hz, 1H), 2.07 (s, 3H), 1.95 (s, 3H), 1.88 (s, 3H), 1.86–1.77 (m, 1H), 1.77–1.68 (m, 1H), 0.90 (t, J = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.5, 170.4, 170.2, 170.0, 132.0 (d, *J* = 6.9 Hz), 131.9 (d, *J* = 6.5 Hz), 118.8, 118.7, 96.6 (d, *J* = 6.8 Hz), 69.0 (d, *J* = 5.3 Hz), 68.8, 68.8 (d, *J* = 5.9 Hz), 67.1, 66.7, 64.5, 61.4, 47.5 (d, *J* = 7.9 Hz), 25.3, 20.6, 20.5, 20.5, 9.9. ³¹P NMR (202 MHz, CDCl₃) δ –1.5.

FT-IR (neat) 3271, 3077, 2966, 2924, 2852, 2105, 1746, 1688, 1554, 1461, 1427, 1371, 1219, 1164, 1138, 1102, 1052, 1019, 990, 956, 873, 806, 736, 648, 627, 533, 475 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₂P: 599.1730, found: 599.1721.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***R***)-2-azidobutanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azidobutanamido)-2-deoxy- β -D-galactopyranose (376 mg, 0.903 mmol). The product

was purified by column chromatography on silica gel $(15\%\rightarrow100\%$ ethyl acetate/hexanes) and then on C-18 silica gel $(5\%\rightarrow100\%$ acetonitrile/water): 293 mg (56%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.51 (d, J = 9.6 Hz, 1H), 6.01–5.91 (m, 2H), 5.76 (dd, J = 5.9, 3.4 Hz, 1H), 5.46 (dd, J = 3.2, 1.3 Hz, 1H), 5.44–5.38 (m, 2H), 5.33–5.29 (m, 2H), 5.21 (dd, J = 11.4, 3.1 Hz, 1H), 4.70–4.58 (m, 5H), 4.42 (ddd, J = 6.6, 6.6, 0.7 Hz, 1H), 4.15–4.07 (m, 2H), 4.00 (dd, J = 6.2, 4.7 Hz, 1H), 2.17 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.96–1.85 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 170.4, 170.2, 169.5, 132.1 (d, *J* = 6.8 Hz), 119.2, 119.0, 96.6 (d, *J* = 6.1 Hz), 69.9 (d, *J* = 5.3 Hz), 68.8, 68.8 (d, *J* = 5.3 Hz), 67.5, 66.9, 65.1, 61.5, 47.6 (d, *J* = 7.8 Hz), 25.1, 20.8, 20.8, 20.8, 9.2. ³¹P NMR (202 MHz, CDCl₃) δ –1.4.

FT-IR (neat) 3274, 3077, 2968, 2927, 2106, 1747, 1689, 1526, 1460, 1427, 1371, 1232, 1164, 1139, 1103, 1021, 991, 942, 875, 808, 677, 649, 626, 593, 535, 471 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₂P: 599.1730, found: 599.1723.



Diallyl 3,4,6-tri-*O***-acetyl-2-((***S***)-2-azido-3-phenylpropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate. The title compound was prepared from 3,4,6-tri-***O***-acetyl-2-((***S***)-2-azido-3-phenylpropanamido)-2-deoxy-\beta-D-galactopyranose (325 mg, 0.679 mmol). The product was purified by column chromatography on silica gel (15%\rightarrow100% ethyl acetate/hexanes) and then on C-18 silica gel (5%\rightarrow100% acetonitrile/water): 188 mg (43%). Light-yellow solid.**


¹H NMR (500 MHz, CDCl₃) δ 7.39 (d, J = 8.9 Hz, 1H), 7.25–7.21 (m, 2H), 7.20–7.16 (m, 3H), 5.89–5.80 (m, 2H), 5.64 (dd, J = 6.3, 3.3 Hz, 1H), 5.41 (dd, J = 3.1, 1.3 Hz, 1H), 5.32–5.24 (m, 2H), 5.22–5.19 (m, 1H), 5.18–5.14 (m, 2H), 4.57 (dddd, J = 11.9, 8.9, 3.1, 3.1 Hz, 1H), 4.53–4.43 (m, 5H), 4.09–4.03 (m, 2H), 3.98 (dd, J = 9.5, 4.3 Hz, 1H), 3.14 (dd, J = 14.1, 4.3 Hz, 1H), 2.90 (dd, J = 14.1, 9.5 Hz, 1H), 2.09 (s, 3H), 1.95 (s, 3H), 1.86 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.3, 170.2, 170.0, 136.4, 132.0 (d, *J* = 7.1 Hz), 131.8 (d, *J* = 6.4 Hz), 129.1, 128.6, 127.1, 118.9, 118.7, 96.5 (d, *J* = 6.9 Hz), 68.6 (d, *J* = 5.5 Hz), 68.6, 68.6 (d, *J* = 5.1 Hz), 67.1, 66.6, 64.5, 61.3, 47.6 (d, *J* = 7.8 Hz), 38.3, 20.6, 20.5, 20.5.

³¹P NMR (202 MHz, CDCl₃) δ –2.5.

FT-IR (neat) 3270, 3076, 3030, 2974, 2116, 1746, 1688, 1559, 1455, 1426, 1371, 1217, 1163, 1140, 1114, 1052, 1017, 987, 940, 876, 805, 731, 700, 647, 626, 601, 590, 556, 529, 482 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₇H₃₅N₄NaO₁₂P: 661.1887, found: 661.1890.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***R***)-2-azido-3-phenylpropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azido-3-phenylpropanamido)-2-deoxy- β -D-galactopyranose (351 mg, 0.734 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 172 mg (37%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 7.26–7.21 (m, 2H), 7.19–7.16 (m, 3H), 7.11 (d, J = 9.1 Hz, 1H), 5.89–5.78 (m, 2H), 5.67 (dd, J = 6.3, 3.3 Hz, 1H), 5.41 (d, J = 2.7 Hz, 1H), 5.31–5.24 (m, 2H), 5.20–5.14 (m, 3H), 4.59 (dddd, J = 12.1, 9.1, 3.2, 3.2 Hz, 1H), 4.51–4.40 (m, 5H), 4.09–4.02 (m, 3H), 3.22 (dd, J = 14.1, 4.0 Hz, 1H), 2.82 (dd, J = 14.2, 9.6 Hz, 1H), 2.09 (s, 3H), 1.94 (s, 3H), 1.87 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.4, 170.1, 169.9, 169.5, 136.3, 131.9 (d, J = 7.4 Hz), 131.9 (d, J = 7.2 Hz), 129.1, 128.5, 127.0, 118.7, 96.3 (d, J = 6.6 Hz), 68.6, 68.6 (d, J = 5.2 Hz), 68.4 (d, J = 5.3 Hz), 67.1, 66.6, 64.7, 61.4, 47.5 (d, J = 7.8 Hz), 37.9, 20.5, 20.5, 20.4.

³¹P NMR (202 MHz, CDCl₃) δ –2.2.

FT-IR (neat) 3271, 3073, 3029, 2957, 2111, 1748, 1691, 1535, 1455, 1427, 1371, 1236, 1163, 1140, 1115, 1022, 991, 945, 877, 743, 701, 675, 649, 625, 594, 528, 473 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₇H₃₅N₄NaO₁₂P: 661.1887, found: 661.1882.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***S***)-2-azido-3-methoxypropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*S*)-2-azido-3-methoxypropanamido)-2-deoxy- β -D-galactopyranose (268 mg, 0.620 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 117 mg (32%). Light-yellow solid.

¹H NMR (500 MHz, CDCl₃) δ 6.89 (d, J = 9.2 Hz, 1H), 5.92–5.83 (m, 2H), 5.65 (dd, J = 6.0, 3.3 Hz, 1H), 5.38 (dd, J = 3.3, 1.3 Hz, 1H), 5.34–5.28 (m, 2H), 5.24–5.19 (m, 2H), 5.15 (dd, J = 11.5, 3.2 Hz, 1H), 4.56–4.47 (m, 5H), 4.36 (dd, J = 6.6, 6.6 Hz, 1H), 4.07–3.98 (m, 3H), 3.72 (dd, J = 10.2, 3.9 Hz, 1H), 3.60 (dd, J = 10.1, 7.0 Hz, 1H), 3.30 (s, 3H), 2.07 (s, 3H), 1.94 (s, 3H), 1.91 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.4, 170.2, 167.0, 167.9, 132.0 (d, *J* = 7.4 Hz), 132.0 (d, *J* = 7.5 Hz) 118.7, 96.3 (d, *J* = 6.4 Hz), 72.6, 68.6 (d, *J* = 5.2 Hz), 68.6 (d, *J* = 5.8 Hz), 68.5, 67.1, 66.7, 62.5, 61.3, 59.1, 47.7 (d, *J* = 8.1 Hz), 20.6, 20.5.

³¹P NMR (202 MHz, CDCl₃) δ –1.4. FT-IR (neat) 3279, 3078, 2959, 2926, 2855, 2108, 1745, 1688, 1527, 1458, 1427, 1371, 1219, 1163, 1113, 1020, 991, 945, 875, 803, 627, 602, 555, 533, 481 cm⁻¹. HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₃P: 615.1679, found: 615.1672.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***R***)-2-azido-3-methoxypropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azido-3-methoxypropanamido)-2-deoxy- β -D-galactopyranose (284 mg, 0.657 mmol). The product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 134 mg (34%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.63 (d, J = 9.5 Hz, 1H), 6.01–5.91 (m, 2H), 5.77 (dd, J = 6.0, 3.4 Hz, 1H), 5.45 (dd, J = 3.3, 1.3 Hz, 1H), 5.44–5.38 (m, 2H), 5.33–5.29 (m, 2H), 5.22 (dd, J = 11.4, 3.2 Hz, 1H), 4.67–4.58 (m, 5H), 4.42 (ddd, J = 6.6, 6.6, 0.8 Hz, 1H), 4.16–4.06 (m, 3H), 3.82 (dd, J = 10.2, 3.5 Hz, 1H), 3.73 (dd, J = 10.2, 6.2 Hz, 1H), 3.39 (s, 3H), 2.16 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.7, 170.4, 170.2, 167.7, 132.1 (d, *J* = 6.7 Hz), 132.1 (d, *J* = 6.9 Hz), 119.2, 119.0, 96.5 (d, *J* = 6.0 Hz), 72.5, 69.0 (d, *J* = 5.4 Hz), 68.9, 68.8 (d, *J* = 5.3 Hz), 67.4, 66.9, 63.1, 61.5, 59.4, 47.8 (d, *J* = 7.9 Hz), 20.8, 20.8, 20.7. ³¹P NMR (202 MHz, CDCl₃) δ –1.4.

FT-IR (neat) 3268, 3081, 2929, 2110, 1748, 1688, 1527, 1459, 1427, 1372, 1234, 1164, 1137, 1115, 1023, 992, 948, 874, 804, 648, 628, 603, 593, 553, 534, 500, 472 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₃P: 615.1679, found: 615.1675.



Diallyl 3,4,6-tri-*O***-acetyl-2-((***R***)-3-azido-2-methylpropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** 3,4,6-Tri-*O*-acetyl-2-((*R*)-3-azido-2-methylpropanamido)-2-deoxy- β -D-galactopyranose (148 mg, 0.355 mmol) and 1*H*-tetrazole (74.6 mg, 1.06 mmol) were suspended in toluene (5.0 mL) in a 20-mL vial. The mixture was sonicated for 1 h, and the toluene was removed under reduced pressure. The vial was charged with nitrogen, and dichloromethane (3.5 mL) was added. The resulting mixture was cooled to 0 °C, and then diallyl *N*,*N*-diisopropylphosphoramidite (0.132 mL, 0.499 mmol) was added dropwise over 5 min. The reaction mixture was stirred at 0 °C


for 1 h, and then cooled to -78 °C. 3-Chloroperbenzoic acid (123 mg, 0.711 mmol) was added, and the mixture was stirred at 0 °C for 1 h. The mixture was diluted with dichloromethane (100 mL), washed with aqueous Na₂SO₃ (10%; 50 mL), saturated aqueous NaHCO₃ (50 mL), and brine (50 mL), dried over Na₂SO₄, and concentrated. The crude product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 121 mg (59%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.89 (d, J = 9.2 Hz, 1H), 5.92–5.83 (m, 2H), 5.63 (dd, J = 6.2, 3.3 Hz, 1H), 5.39 (dd, J = 3.1, 1.3 Hz, 1H), 5.33–5.29 (m, 2H), 5.23–5.20 (m, 2H), 5.16 (dd, J = 11.5, 3.1 Hz, 1H), 4.62 (dddd, J = 12.1, 9.2, 3.2, 3.2 Hz, 1H), 4.57–4.48 (m, 4H), 4.44 (dd, J = 6.6, 6.6 Hz, 1H), 4.08– 4.02 (m, 2H), 3.52 (dd, J = 12.1, 7.9 Hz, 1H), 3.20 (dd, J = 12.1, 5.9 Hz, 1H), 2.50–2.43 (m, 1H), 2.08 (s, 3H), 1.95 (s, 3H), 1.89 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 174.4, 170.5, 170.3, 170.1, 132.2 (d, J = 6.9 Hz), 132.0 (d, J = 6.7 Hz), 118.8, 118.7, 97.0 (d, J = 7.1 Hz), 68.7, 68.6 (d, J = 6.1 Hz), 68.6 (d, J = 5.0 Hz), 67.4, 66.8, 61.5, 53.7, 47.3 (d, J = 7.6 Hz), 40.7, 20.6, 20.6, 20.5, 15.5. ³¹P NMR (202 MHz, CDCl₃) δ -2.5.

FT-IR (neat) 3280, 3082, 2975, 2938, 2880, 2101, 1745, 1679, 1544, 1458, 1426, 1371, 1216, 1163, 1141, 1109, 1053, 1017, 989, 942, 805, 733, 702, 645, 626, 591, 542, 529, 474 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₂P: 599.1730, found: 599.1715.




Diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-3-azido-2-methylpropanamido)-2-deoxy-α-D-galactopyranosyl-1-phosphate. 3,4,6-Tri-*O*-acetyl-2-((*S*)-3-azido-2-

methylpropanamido)-2-deoxy-β-D-galactopyranose (247 mg, 0.593 mmol) and 1*H*tetrazole (125 mg, 1.78 mmol) were suspended in toluene (5.0 mL) in a 20-mL vial. The mixture was sonicated for 1 h, and the toluene was removed under reduced pressure. The vial was charged with nitrogen, and dichloromethane (5.9 mL) was added. The resulting mixture was cooled to 0 °C, and then diallyl *N*,*N*-diisopropylphosphoramidite (0.220 mL, 0.832 mmol) was added dropwise over 5 min. The reaction mixture was stirred at 0 °C for 1 h, and then cooled to -78 °C. 3-Chloroperbenzoic acid (205 mg, 1.19 mmol) was added, and the mixture was stirred at 0 °C for 1 h. The mixture was diluted with dichloromethane (100 mL), washed with aqueous Na₂SO₃ (10%; 50 mL), saturated aqueous NaHCO₃ (50 mL), and brine (50 mL), dried over Na₂SO₄, and concentrated. The crude product was purified by column chromatography on silica gel (15% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (5% \rightarrow 100% acetonitrile/water): 249 mg (73%). Viscous light-yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 6.83 (d, J = 9.0 Hz, 1H), 5.92–5.80 (m, 2H), 5.63 (dd, J = 6.4, 3.3 Hz, 1H), 5.40 (dd, J = 3.2, 1.3 Hz, 1H), 5.33–5.27 (m, 2H), 5.24–5.18 (m, 2H), 5.15 (dd, J = 11.5, 3.2 Hz, 1H), 4.61 (dddd, J = 12.0, 9.0, 3.2, 3.2 Hz, 1H), 4.55–4.46 (m, 4H), 4.43 (dd, J = 6.6, 6.6 Hz, 1H), 4.08–4.01 (m, 2H), 3.44 (dd, J = 12.0, 8.7 Hz, 1H), 3.21 (dd, J = 12.0, 5.4 Hz, 1H), 2.49–2.42 (m, 1H), 2.09 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 174.2, 170.9, 170.4, 170.2, 132.2 (d, *J* = 6.8 Hz), 132.0 (d, *J* = 6.6 Hz), 119.1, 119.1, 97.0 (d, *J* = 6.7 Hz), 68.8 (d, *J* = 5.4 Hz), 68.8, 68.7 (d, *J* = 5.3 Hz), 67.3, 66.9, 61.6, 54.1, 47.6 (d, *J* = 7.6 Hz), 41.0, 20.8, 20.7, 20.6, 15.3. ³¹P NMR (202 MHz, CDCl₃) δ –2.4.

FT-IR (neat) 3283, 3085, 2975, 2938, 2876, 2100, 1746, 1680, 1542, 1458, 1427, 1372, 1232, 1163, 1141, 1110, 1052, 1021, 991, 948, 888, 711, 676, 650, 626, 603, 526, 477 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₂H₃₃N₄NaO₁₂P: 599.1730, found: 599.1720.



Diallyl 3,4,6-tri-O-acetyl-2-((R)-2-methylpent-4-ynamido)-2-deoxy-α-D-

galactopyranosyl-1-phosphate. The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*R*)-2-methylpent-4-ynamido)-2-deoxy- β -D-galactopyranose (148 mg, 0.371 mmol). The product was purified by column chromatography (12% \rightarrow 100% ethyl acetate/hexanes): 179 mg (86%). White solid.


¹H NMR (500 MHz, CDCl₃) δ 6.53 (d, J = 9.2 Hz, 1H), 5.93–5.83 (m, 2H), 5.65 (dd, J = 6.0, 3.3 Hz, 1H), 5.40 (dd, J = 3.2, 1.3 Hz, 1H), 5.35–5.30 (m, 2H), 5.25–5.21 (m, 2H), 5.16 (dd, J = 11.5, 3.1 Hz, 1H), 4.63 (dddd, J = 12.2, 9.3, 3.2, 3.2 Hz, 1H), 4.55–4.50 (m, 4H), 4.41 (dd, J = 6.7, 6.7 Hz, 1H), 4.01–4.01 (m, 2H), 2.45–2.38 (m, 2H), 2.27–2.21 (m, 1H), 2.09 (s, 3H), 1.98 (dd, J = 2.5, 2.5 Hz, 1H), 1.96 (s, 3H), 1.90 (s, 3H), 1.13 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 175.2, 170.6, 170.3, 170.1, 132.2 (d, *J* = 6.8 Hz), 132.0 (d, *J* = 6.7 Hz), 119.0, 118.9, 97.1 (d, *J* = 6.9 Hz), 81.8, 70.2, 68.7 (d, *J* = 5.3 Hz), 68.7, 68.6 (d, *J* = 5.3 Hz), 67.4, 66.9, 61.5, 47.2 (d, *J* = 7.8 Hz), 40.0, 22.6, 20.7, 20.6, 20.6, 17.1.

³¹P NMR (202 MHz, CDCl₃) δ –2.1.

FT-IR (neat) 3296, 2973, 2251, 1746, 1674, 1542, 1459, 1426, 1371, 1232, 1163, 1140, 1103, 1053, 1018, 988, 947, 907, 726, 646, 593, 552, 527, 473 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₄H₃₄NNaO₁₂P: 582.1716, found: 582.1708.



Diallyl 3,4,6-tri-O-acetyl-2-((S)-2-methylpent-4-ynamido)-2-deoxy-α-D-


galactopyranosyl-1-phosphate. The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*S*)-2-methylpent-4-ynamido)-2-deoxy- β -D-galactopyranose (219 mg, 0.548 mmol). The product was purified by column chromatography on silica gel (12% \rightarrow 100% ethyl acetate/hexanes) and then on C-18 silica gel (10% \rightarrow 100% acetonitrile/water): 234 mg (76%). Viscous colorless oil.

¹H NMR (500 MHz, CDCl₃) δ 6.44 (d, J = 9.2 Hz, 1H), 5.94–5.83 (m, 2H), 5.65 (dd, J = 6.1, 3.3 Hz, 1H), 5.40 (d, J = 2.3 Hz, 1H), 5.36–5.29 (m, 2H), 5.26–5.20 (m, 2H), 5.13 (dd, J = 11.5, 3.2 Hz, 1H), 4.64 (dddd, J = 12.2, 9.3, 3.2, 3.2 Hz, 1H), 4.56–4.49 (m, 4H), 4.40 (dd, J = 6.5, 6.5 Hz, 1H), 4.09–4.02 (m, 2H), 2.44–2.34 (m, 2H), 2.27–2.19 (m, 1H), 2.10 (s, 3H), 1.96 (s, 3H), 1.94 (dd, J = 2.7, 2.7 Hz, 1H), 1.91 (s, 3H), 1.14 (d, J = 6.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 175.0, 170.6, 170.3, 170.2, 132.1 (d, *J* = 6.7 Hz), 132.0 (d, *J* = 6.7 Hz), 119.0, 119.0, 97.0 (d, *J* = 6.8 Hz), 81.9, 70.1, 68.7 (d, *J* = 5.3 Hz), 68.7, 68.6 (d, *J* = 5.4 Hz), 67.5, 66.8, 61.5, 47.2 (d, *J* = 7.8 Hz), 40.1, 23.0, 20.8, 20.7, 20.6, 17.0.

³¹P NMR (202 MHz, CDCl₃) δ –2.0.

FT-IR (neat) 3281, 2976, 2938, 2248, 1745, 1676, 1540, 1459, 1426, 1371, 1219, 1164, 1139, 1104, 1052, 1018, 989, 945, 910, 728, 645, 600, 591, 526, 481 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₄H₃₄NNaO₁₂P: 582.1716, found: 582.1702.



Diallyl 3,4,6-tri-*O***-acetyl-2-((***R***)-2-methylhex-5-ynamido)-2-deoxy-α-Dgalactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*acetyl-2-((*R*)-2-methylhex-5-ynamido)-2-deoxy-β-D-galactopyranose (150 mg, 0.363 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 173 mg (83%). White solid.


¹H NMR (500 MHz, CDCl₃) δ 6.29 (d, J = 9.2 Hz, 1H), 5.93–5.84 (m, 2H), 5.64 (dd, J = 5.8, 3.3 Hz, 1H), 5.39 (dd, J = 3.3, 1.4 Hz, 1H), 5.35–5.29 (m, 2H), 5.24–5.20 (m, 2H), 5.15 (dd, J = 11.5, 3.1 Hz, 1H), 4.63 (dddd, J = 12.6, 9.4, 3.3, 3.3 Hz, 1H), 4.57–4.48 (m, 4H), 4.39 (ddd, J = 6.4, 6.4, 1.2 Hz, 1H), 4.09–4.00 (m, 2H), 2.40–2.33 (m, 1H), 2.17–

2.06 (m, 2H), 2.09 (s, 3H), 1.96 (s, 3H), 1.91 (s, 3H), 1.90 (dd, J = 2.7, 2.7 Hz, 1H), 1.85–1.78 (m, 1H), 1.53–1.46 (m, 1H), 1.04 (d, J = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 176.3, 170.6, 170.3, 170.1, 132.2 (d, J = 6.6 Hz), 132.0 (d, J = 6.6 Hz), 118.9, 118.8, 97.1 (d, J = 6.9 Hz), 83.5, 69.1, 68.6 (d, J = 5.1 Hz), 68.6, 68.6 (d, J = 6.3 Hz), 67.5, 66.9, 61.5, 47.2 (d, J = 8.0 Hz), 39.8, 31.9, 20.7, 20.6, 20.6, 17.6, 16.3.

³¹P NMR (202 MHz, CDCl₃) δ –1.9.

FT-IR (neat) 3287, 2966, 2935, 1745, 1676, 1535, 1459, 1428, 1371, 1218, 1162, 1138, 1109, 1054, 1017, 990, 943, 808, 734, 627, 600, 527, 472 cm⁻¹.

HRMS (ESI) *m/z* ([M+Na]⁺) calcd for C₂₅H₃₆NNaO₁₂P: 596.1873, found: 596.1866.




Diallyl 3,4,6-tri-*O***-acetyl-2-((***S***)-2-methylhex-5-ynamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate.** The title compound was prepared from 3,4,6-tri-*O*-acetyl-2-((*S*)-2-methylhex-5-ynamido)-2-deoxy- β -D-galactopyranose (169 mg, 0.409 mmol). The product was purified by column chromatography (15% \rightarrow 100% ethyl acetate/hexanes): 185 mg (79%). White solid.

¹H NMR (500 MHz, CDCl₃) δ 6.36 (d, J = 9.1 Hz, 1H), 5.92–5.82 (m, 2H), 5.64 (dd, J = 6.2, 3.3 Hz, 1H), 5.39 (dd, J = 3.2, 1.3 Hz, 1H), 5.34–5.28 (m, 2H), 5.24–5.19 (m, 2H), 5.12 (dd, J = 11.6, 3.1 Hz, 1H), 4.62 (dddd, J = 12.1, 9.1, 3.2, 3.2 Hz, 1H), 4.54–4.47 (m, 4H), 4.38 (ddd, J = 6.5, 6.5, 1.4 Hz, 1H), 4.08–4.01 (m, 2H), 2.41–2.34 (m, 1H), 2.17–2.07 (m, 1H), 2.09 (s, 3H), 2.06–1.99 (m, 1H), 1.95 (s, 3H), 1.92 (s, 3H), 1.89 (dd, J = 2.6, 2.6 Hz, 1H), 1.79–1.70 (m, 1H), 1.52–1.46 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 176.1, 170.5, 170.3, 170.1, 132.2 (d, J = 6.8 Hz), 132.0 (d, J = 6.6 Hz), 118.9, 118.8, 97.0 (d, J = 6.9 Hz), 83.3, 69.3, 68.6 (d, J = 6.5 Hz), 68.6, 68.6 (d, J = 7.0 Hz), 67.3, 66.7, 61.5, 47.0 (d, J = 7.7 Hz), 39.6, 32.4, 20.7, 20.6, 17.4, 16.2.


³¹P NMR (202 MHz, CDCl₃) δ –2.1.

FT-IR (neat) 3283, 3079, 2967, 2937, 1745, 1676, 1540, 1458, 1428, 1371, 1217, 1163, 1139, 1110, 1052, 1017, 990, 944, 807, 734, 711, 642, 627, 601, 528, 472, 433 cm⁻¹. HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₅H₃₆NNaO₁₂P: 596.1873, found: 596.1861.



Representative procedure for the preparation of UDP-*N*-acetyl- α -D-galactosamine derivatives (Route 1)


Tri-O-acetylated N-acetyl-α-D-galactosamine 1-phosphate derivatives were prepared from tri-O-acetvlated N-acetvl- α -D-galactosamine 1-diallyl phosphates according to a literature procedure.¹⁹ Then, UDP-sugars were prepared using a modified literature procedure.^{19,20} A mixture of the sugar 1-phosphate (0.200 mmol), uridine 5'monophosphomorpholidate 4-morpholine-N,N'-dicyclohexylcarboxamidine salt (224 mg, 0.326 mmol), 1-methylimidazole hydrochloride (128 mg, 1.08 mmol), and NEt₃ (55.8 µL, 0.400 mmol) in DMF (3.92 mL) in a 25-mL round-bottom flask was stirred at r.t. for 12 h. The tri-O-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (MeOH/water; water was doped with 10 mM n-Bu₃NH•HCO₃). Aqueous *n*-Bu₃NH•HCO₃ solution (10 mM) was prepared by bubbling CO_2 through a solution of *n*-Bu₃NH (10 mM) in water until all *n*-Bu₃NH dissolved into the water. Pure fractions were collected, concentrated, redissolved in water (100 mL), rinsed with CH₂Cl₂ (3 x 50 mL), and concentrated. The compound was dissolved in MeOH/water/NEt₃ (5 mL, 5:2:1) in a 25-mL round-bottom flask, and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on C-18 silica gel (MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). Pure fractions were collected, concentrated, redissolved in water (100 mL), rinsed with CH₂Cl₂ (3 x 50 mL), and concentrated. Finally, the purified compound was passed through a Bio-Rad AG® 50W-X8 resin (sodium form) and lyophilized.



UDP-Sugar (S)-3. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-2-azidopropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (415 mg, 0.738 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (10% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 36.8 min): 148 mg (28%). White solid.

¹H NMR (500 MHz, D₂O) δ 7.94 (d, J = 8.1 Hz, 1H), 5.97–5.94 (m, 2H), 5.56 (dd, J = 7.0, 3.4 Hz, 1H), 4.37–4.33 (m, 2H), 4.29–4.21 (m, 4H), 4.21–4.15 (m, 2H), 4.04 (d, J = 3.0 Hz, 1H), 3.98 (dd, J = 11.0, 3.2 Hz, 1H), 3.79–3.72 (m, 2H), 1.47 (d, J = 7.1 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 175.0, 166.8, 152.4, 142.3, 103.2, 95.3 (d, J = 6.2 Hz), 89.2, 83.8 (d, J = 9.0 Hz), 74.4, 72.7, 70.2, 69.1, 68.1, 65.6 (d, J = 4.9 Hz), 61.6, 58.8, 50.5 (d, J = 8.6 Hz), 17.5.


³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 20.8 Hz), –12.3 (d, J = 20.8 Hz). FT-IR (neat) 3234, 2115, 1665, 1544, 1468, 1425, 1392, 1342, 1227, 1114, 1076, 1037, 985, 916, 861, 814, 780, 766, 717, 685, 620, 533, 503, 492, 444 cm⁻¹. HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₈H₂₇N₆Na₂O₁₇P₂: 707.0703, found: 707.0706.



UDP-Sugar (*R*)-3. The title compound was prepared from diallyl 3,4,6-tri-O-acetyl-2-((R)-2-azidopropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (132 mg, 0.235) mmol). The tri-O-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel ($10\% \rightarrow 60\%$ MeOH/water; water was doped with 10 mM n-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM n-Bu₃NH•HCO₃: 20 mL/min: $t_r = 51.4$ min): 53.6 mg (32%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.93 (d, J = 8.1 Hz, 1H), 5.97–5.93 (m, 2H), 5.54 (dd, J =7.1, 3.5 Hz, 1H), 4.37–4.32 (m, 2H), 4.28–4.23 (m, 2H), 4.23–4.15 (m, 4H), 4.03 (d, J =3.1 Hz, 1H, 3.98 (dd, J = 10.9, 3.2 Hz, 1H), 3.78-3.71 (m, 2H), 1.47 (d, J = 6.9 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 174.8, 167.3, 152.7, 142.2, 103.3, 95.1 (d, J = 6.2 Hz), 89.2, 83.7 (d, J = 9.0 Hz), 74.4, 72.7, 70.2, 69.0, 67.9, 65.6 (d, J = 4.9 Hz), 61.6, 58.8, 50.6 (d, J = 8.2 Hz), 17.1. ³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.6 Hz), –12.3 (d, J = 20.7 Hz). FT-IR (neat) 3254, 2115, 1669, 1536, 1464, 1426, 1391, 1346, 1232, 1116, 1078, 1037,

F1-IR (neat) 3254, 2115, 1669, 1536, 1464, 1426, 1391, 1346, 1232, 1116, 1078, 10. 984, 921, 858, 814, 779, 718, 689, 630, 506 cm⁻¹.

HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₈H₂₇N₆Na₂O₁₇P₂: 707.0703, found: 707.0699.




UDP-Sugar (*S*)-4. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-2-azidobutanamido)-2-deoxy-α-D-galactopyranosyl-1-phosphate (124 mg, 0.215 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0%→100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (10%→60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 53.5 min): 70.1 mg (45%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.92 (d, *J* = 8.1 Hz, 1H), 5.97–5.92 (m, 2H), 5.55 (dd, *J* =

¹H NMR (500 MHz, D₂O) δ 7.92 (d, J = 8.1 Hz, 1H), 5.97–5.92 (m, 2H), 5.55 (dd, J = 6.9, 3.5 Hz, 1H), 4.36–4.32 (m, 2H), 4.30–4.14 (m, 5H), 4.09 (dd, J = 6.6, 6.6 Hz, 1H), 4.02 (d, J = 3.2 Hz, 1H), 3.95 (dd, J = 11.0, 3.2 Hz, 1H), 3.78–3.71 (m, 2H), 1.89–1.75 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H).

¹³C NMR (126 MHz, D₂O) δ 174.2, 167.4, 152.8, 142.2, 103.3, 95.4 (d, J = 6.6 Hz), 89.2, 83.7 (d, J = 9.1 Hz), 74.4, 72.7, 70.3, 69.2, 68.0, 65.6 (d, J = 5.4 Hz), 64.6, 61.6, 50.5 (d, J = 8.6 Hz), 25.7, 9.8.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, *J* = 20.8 Hz), –12.3 (d, *J* = 20.2 Hz). FT-IR (neat) 3294, 2107, 1671, 1537, 1465, 1427, 1392, 1238, 1118, 1080, 1053, 987, 919, 855, 814, 779, 714, 685, 611, 504, 438 cm⁻¹.


HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0852.



UDP-Sugar (*R*)-4. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azidobutanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (293 mg, 0.508 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (10% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 53.8 min): 113 mg (31%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.95 (d, J = 8.2 Hz, 1H), 5.97–5.95 (m, 2H), 5.56 (dd, J = 6.8, 3.5 Hz, 1H), 4.38–4.34 (m, 2H), 4.31–4.16 (m, 5H), 4.07–4.03 (m, 2H), 4.00 (dd, J = 10.9, 3.1 Hz, 1H), 3.80–3.72 (m, 2H), 1.94–1.76 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 174.0, 166.8, 152.3, 142.3, 103.2, 95.2 (d, J = 5.7 Hz), 89.2, 83.7 (d, J = 8.9 Hz), 74.4, 72.6, 70.2, 69.0, 67.9, 65.5 (d, J = 3.8 Hz), 64.7, 61.6, 50.5 (d, J = 8.5 Hz), 25.3, 9.9.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.8 Hz), –12.4 (d, J = 20.6 Hz). FT-IR (neat) 3232, 2109, 1669, 1464, 1429, 1391, 1232, 1115, 1079, 1038, 987, 918, 811, 717, 687, 511, 444, 425 cm⁻¹.

HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0860.




UDP-Sugar (S)-5. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-2-azido-3-phenylpropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (188 mg, 0.294 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:0, 10:0, 60:50; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 52.4 min): 107 mg (46%). White solid.

¹H NMR (500 MHz, D₂O) δ 7.86 (dd, J = 8.1, 1.3 Hz, 1H), 7.37–7.32 (m, 4H), 7.32–7.27 (m, 1H), 5.90 (d, J = 3.5 Hz, 1H), 5.85 (d, J = 8.0 Hz, 1H), 5.56 (dd, J = 7.1, 3.4 Hz, 1H), 4.43 (dd, J = 9.2, 5.3 Hz, 1H), 4.32–4.13 (m, 7H), 4.01 (d, J = 2.5 Hz, 1H), 3.94 (dd, J = 11.1, 3.0 Hz, 1H), 3.79–3.70 (m, 2H), 3.20 (dd, J = 14.1, 5.1 Hz, 1H), 3.01 (dd, J = 14.0, 9.4 Hz, 1H).

¹³C NMR (126 MHz, D₂O) δ 173.6, 166.9, 152.4, 142.2, 137.2, 130.1, 129.4, 127.9, 103.2, 95.4 (d, *J* = 5.3 Hz), 89.2, 83.8 (d, *J* = 9.3 Hz), 74.5, 72.8, 70.3, 69.2, 68.2, 65.7 (d, *J* = 4.9 Hz), 64.6, 61.7, 50.6 (d, *J* = 8.6 Hz), 38.5.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 21.4 Hz), –12.2 (d, J = 20.6 Hz). FT-IR (neat) 3250, 2115, 1670, 1539, 1458, 1426, 1394, 1338, 1235, 1113, 1079, 1052, 987, 921, 859, 812, 742, 700, 621, 501 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₄H₃₀N₆Na₃O₁₇P₂: 805.0836, found: 805.0833.



UDP-Sugar (*R*)-5. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*R*)-2-azido-3-phenylpropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (172 mg, 0.269 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:0, 10:0, 60:50; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 51.5 min): 52.2 mg (25%). White solid.


¹H NMR (500 MHz, D₂O) δ 7.80 (d, J = 8.0 Hz, 1H), 7.40–7.25 (m, 5H), 5.85 (d, J = 3.3 Hz, 1H), 5.80 (d, J = 8.2 Hz, 1H), 5.54 (dd, J = 6.8, 3.4 Hz, 1H), 4.38 (dd, J = 10.0, 4.2 Hz, 1H), 4.30–4.17 (m, 6H), 4.17–4.11 (m, 1H), 4.04 (d, J = 3.1 Hz, 1H), 3.98 (dd, J = 11.0, 3.0 Hz, 1H), 3.80–3.71 (m, 2H), 3.27 (dd, J = 14.2, 4.2 Hz, 1H), 2.98 (dd, J = 14.2, 10.0 Hz, 1H).

¹³C NMR (126 MHz, D₂O) δ 173.4, 166.9, 152.3, 142.2, 137.2, 130.0, 129.4, 127.8, 103.2, 95.3 (d, *J* = 5.9 Hz), 89.4, 83.7 (d, *J* = 9.0 Hz), 74.4, 72.8, 70.2, 69.1, 68.2, 65.8 (d, *J* = 4.8 Hz), 64.6, 61.7, 50.7 (d, *J* = 8.4 Hz), 38.0.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 20.8 Hz), –12.4 (d, J = 21.4 Hz).

FT-IR (neat) 3294, 2114, 1665, 1543, 1459, 1425, 1390, 1342, 1232, 1112, 1079, 1053, 986, 921, 861, 812, 741, 699, 626, 510 cm⁻¹.


HRMS (ESI) m/z ([M+H]⁺) calcd for C₂₄H₃₁N₆Na₂O₁₇P₂: 783.1016, found: 783.1027.



UDP-Sugar (S)-6. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((S)-2-azido-3-methoxypropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (117 mg, 0.197 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (10% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 52.4 min): 72.5 mg (50%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.94 (d, J = 8.1 Hz, 1H), 5.98–5.93 (m, 2H), 5.56 (dd, J = 6.9, 3.0 Hz, 1H), 4.50–4.46 (m, 1H), 4.38–4.32 (m, 2H), 4.31–4.15 (m, 5H), 4.03 (d, J = 3.2 Hz, 1H), 3.98 (dd, J = 10.9, 2.8 Hz, 1H), 3.84–3.70 (m, 4H), 3.41 (s, 3H). ¹³C NMR (126 MHz, D₂O) δ 171.3, 166.8, 152.4, 142.3, 103.2, 95.2 (d, J = 6.4 Hz), 89.2, 83.8 (d, J = 9.1 Hz), 74.4, 72.8, 72.7, 70.2, 69.1, 68.0, 65.7 (d, J = 5.0 Hz), 62.7, 61.6, 59.2, 50.6 (d, J = 8.6 Hz).

³¹P NMR (202 MHz, D₂O) δ –10.4 (d, *J* = 19.4 Hz), –12.2 (d, *J* = 17.8 Hz). FT-IR (neat) 3250, 2111, 1670, 1539, 1466, 1427, 1392, 1234, 1111, 1079, 1056, 986, 920, 854, 812, 766, 715, 690, 625, 512 cm⁻¹.


HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₈P₂: 737.0809, found: 737.0800.



UDP-Sugar (R)-6. The title compound was prepared from diallyl 3,4,6-tri-O-acetyl-2- $((R)-2-azido-3-methoxypropanamido)-2-deoxy-\alpha-D-galactopyranosyl-1-phosphate (133)$ mg, 0.224 mmol). The tri-O-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel ($0\% \rightarrow 100\%$ MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel ($10\% \rightarrow 60\%$ MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent Microsorb 100-5 C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; $t_r = 52.4$ min): 48.7 mg (29%). White solid. ¹H NMR (500 MHz, D_2O) δ 7.95 (d, J = 8.1 Hz, 1H), 5.99–5.94 (m, 2H), 5.56 (dd, J =6.4, 2.9 Hz, 1H), 4.44 (dd, J = 6.4, 3.9 Hz, 1H), 4.39–4.33 (m, 2H), 4.31–4.16 (m, 5H), 4.04 (d, J = 3.1 Hz, 1H), 4.01 (dd, J = 11.0, 2.6 Hz, 1H), 3.90-3.70 (m, 4H), 3.42 (s, 3H).¹³C NMR (126 MHz, D₂O) δ 171.2, 168.7, 153.8, 142.1, 103.3, 95.1 (d, J = 6.4 Hz), 89.3, 83.7 (d, J = 9.0 Hz), 74.4, 72.7, 72.3, 70.3, 69.0, 67.9, 65.7 (d, J = 5.3 Hz), 62.8, 61.6, 59.3, 50.74 (d, J = 8.3 Hz). ³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.8 Hz), –12.3 (d, J = 20.8 Hz). FT-IR (neat) 3246, 2109, 1668, 1466, 1427, 1391, 1232, 1110, 1079, 1056, 986, 917,

857, 813, 768, 714, 688, 624, 506 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₁₉H₂₈N₆Na₃O₁₈P₂: 759.0628, found: 759.0619.




UDP-Sugar (*R*)-8. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*R*)-3-azido-2-methylpropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (67.0 mg, 0.116 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (40% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 39.9 min): 18.8 mg (22%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.92 (d, *J* = 8.1 Hz, 1H), 5.97–5.92 (m, 2H), 5.53 (dd, *J* =

 $\begin{array}{l} \text{HNMR} (500 \text{ MHz}, D_2 \text{O}) \text{ o} 7.92 (\text{d}, J = 8.1 \text{ Hz}, 1\text{H}), 5.97 = 3.92 (\text{III}, 2\text{H}), 5.35 (\text{dd}, J = 6.8, 3.4 \text{ Hz}, 1\text{H}), 4.36 = 4.32 (\text{m}, 2\text{H}), 4.30 = 4.14 (\text{m}, 5\text{H}), 4.01 (\text{d}, J = 3.1 \text{ Hz}, 1\text{H}), 3.95 (\text{dd}, J = 10.9, 3.2 \text{ Hz}, 1\text{H}), 3.77 = 3.69 (\text{m}, 2\text{H}), 3.52 (\text{dd}, J = 12.4, 8.2 \text{ Hz}, 1\text{H}), 3.36 (\text{dd}, J = 12.4, 5.8 \text{ Hz}, 1\text{H}), 2.85 = 2.77 (\text{m}, 1\text{H}), 1.14 (\text{d}, J = 7.0 \text{ Hz}, 3\text{H}). \end{array}$

¹³C NMR (126 MHz, D₂O) δ 178.7, 168.3, 153.5, 142.2, 103.3, 95.6 (d, J = 6.5 Hz), 89.2, 83.8 (d, J = 8.9 Hz), 74.4, 72.7, 70.3, 69.2, 68.3, 65.7 (d, J = 5.4 Hz), 61.6, 54.1, 50.3 (d, J = 8.7 Hz), 41.0, 15.4.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 20.8 Hz), –12.4 (d, J = 20.8 Hz). FT-IR (neat) 3263, 2105, 1671, 1549, 1464, 1430, 1391, 1350, 1235, 1115, 1080, 1058, 1035, 986, 921, 814, 717, 697, 617, 513 cm⁻¹.

HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0845.




UDP-Sugar (*S*)-8. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-3-azido-2-methylpropanamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (48.3 mg, 0.0838 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (40% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 41.2 min): 14.4 mg (24%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.96 (d, J = 8.1 Hz, 1H), 5.99–5.95 (m, 2H), 5.54 (dd, J = 7.1, 3.4 Hz, 1H), 4.39–4.34 (m, 2H), 4.31–4.16 (m, 5H), 4.04 (d, J = 3.2 Hz, 1H), 3.98 (dd, J = 10.9, 2.9 Hz, 1H), 3.80–3.69 (m, 2H), 3.49 (dd, J = 12.3, 9.1 Hz, 1H), 3.41 (dd, J = 12.4, 5.4 Hz, 1H), 2.86–2.77 (m, 1H), 1.16 (d, J = 7.0 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 178.8, 167.1, 152.6, 142.3, 103.3, 95.4 (d, J = 6.1 Hz), 89.2,

83.9 (d, J = 9.3 Hz), 74.4, 72.7, 70.3, 69.1, 68.2, 65.6 (d, J = 4.1 Hz), 61.7, 54.2, 50.4 (d, J = 8.2 Hz), 41.0, 15.4.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 20.8 Hz), –12.3 (d, J = 21.2 Hz).

FT-IR (neat) 3276, 2106, 1673, 1548, 1465, 1427, 1392, 1347, 1235, 1115, 1079, 1058, 1035, 986, 919, 814, 782, 768, 714, 696, 643, 625, 509 cm⁻¹.

HRMS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0853.




UDP-Sugar (*R*)-12. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*R*)-2-methylpent-4-ynamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (64.6 mg, 0.115 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (30% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 38.8 min): 44.8 mg (55%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.94 (d, *J* = 8.0 Hz, 1H), 5.97–5.93 (m, 2H), 5.51 (dd, *J* = 6.5, 3.4 Hz, 1H), 4.37–4.33 (m, 2H), 4.30–4.15 (m, 5H), 4.03 (d, *J* = 3.0 Hz, 1H), 3.96 (dd, *J* = 11.0, 3.2 Hz, 1H), 3.78–3.69 (m, 2H), 2.75 (apparent sextet, *J* = 7.0 Hz, 1H), 2.47–2.31 (m, 3H), 1.18 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, D₂O) δ 179.7, 167.7, 153.0, 142.2, 103.3, 95.7 (d, *J* = 6.5 Hz), 89.1, 83.8 (d, *J* = 9.5 Hz), 83.2, 74.4, 72.7, 71.6, 70.3, 69.1, 68.2, 65.6 (d, *J* = 4.6 Hz), 61.6, 50.2 (d, *J* = 9.0 Hz), 40.2, 23.0, 17.1.

³¹P NMR (202 MHz, D₂O) δ –10.5 (d, J = 20.8 Hz), –12.5 (d, J = 20.8 Hz). FT-IR (neat) 3274, 1672, 1539, 1463, 1428, 1394, 1339, 1241, 1117, 1078, 1054, 986, 919, 814, 780, 714, 690, 655, 628, 513 cm⁻¹.

HRMS (ESI) m/z ([M+H]⁺) calcd for C₂₁H₃₀N₃Na₂O₁₇P₂: 704.0846, found: 704.0848.




UDP-Sugar (S)-12. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*S*)-2-methylpent-4-ynamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (59.0 mg, 0.105 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (30% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 39.1 min): 38.0 mg (51%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.93 (d, *J* = 8.1 Hz, 1H), 5.97–5.93 (m, 2H), 5.52 (dd, *J* = 7.0, 3.4 Hz, 1H), 4.36–4.32 (m, 2H), 4.29–4.15 (m, 5H), 4.02 (d, *J* = 3.2 Hz, 1H), 3.95 (dd, *J* = 11.0, 3.2 Hz, 1H), 3.78–3.69 (m, 2H), 2.79–2.71 (m, 1H), 2.46–2.39 (m, 1H), 2.36–2.30 (m, 2H), 1.18 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, D₂O) δ 179.7, 167.8, 153.1, 142.2, 103.3, 95.4 (d, *J* = 6.4 Hz), 89.1, 83.8 (d, *J* = 9.1 Hz), 83.4, 74.4, 72.7, 71.2, 70.3, 69.1, 68.1, 65.6 (d, *J* = 5.3 Hz), 61.6, 50.3 (d, *J* = 8.6 Hz), 40.4, 22.9, 17.3.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, *J* = 20.8 Hz), –12.3 (d, *J* = 20.8 Hz). FT-IR (neat) 3260, 1675, 1541, 1463, 1427, 1392, 1237, 1117, 1079, 1055, 988, 920, 860, 816, 717, 688, 664, 647, 623, 510 cm⁻¹.

HRMS (ESI) m/z ([M+Na]⁺) calcd for C₂₁H₂₉N₃Na₃O₁₇P₂: 726.0665, found: 726.0660.




UDP-Sugar (*R*)-14. The title compound was prepared from diallyl 3,4,6-tri-*O*-acetyl-2-((*R*)-2-methylhex-5-ynamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (62.5 mg, 0.109 mmol). The tri-*O*-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel (30% \rightarrow 60% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 42.8 min): 38.7 mg (50%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.93 (d, *J* = 8.1 Hz, 1H), 5.98–5.93 (m, 2H), 5.52 (dd, *J* = 6.6, 3.4 Hz, 1H), 4.36–4.32 (m, 2H), 4.28–4.15 (m, 5H), 4.02 (d, *J* = 2.8 Hz, 1H), 3.95 (dd, *J* = 11.0, 3.2 Hz, 1H), 3.78–3.69 (m, 2H), 2.66–2.58 (m, 1H), 2.32 (t, *J* = 2.6 Hz, 1H), 2.28–2.13 (m, 2H), 1.84–1.75 (m, 1H), 1.64–1.56 (m, 1H), 1.12 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 181.1, 167.6, 153.0, 142.3, 103.3, 95.6 (d, *J* = 6.7 Hz), 89.2, 85.7, 83.8 (d, *J* = 8.8 Hz), 74.4, 72.6, 70.2, 69.1, 68.3, 65.6 (d, *J* = 5.1 Hz), 61.6, 50.2 (d, *J* = 8.9 Hz), 40.5, 32.5, 17.7, 16.5.


³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.6 Hz), –12.5 (d, J = 20.6 Hz). FT-IR (neat) 3266, 1674, 1538, 1465, 1430, 1392, 1349, 1234, 1117, 1079, 1057, 1038,

987, 918, 850, 813, 775, 687, 631, 511 cm⁻¹.

MS (ESI) m/z ([M+H]⁺) calcd for C₂₂H₃₂N₃Na₂O₁₇P₂: 718.1002, found: 718.0994.




UDP-Sugar (S)-14. The title compound was prepared from dially 3,4,6-tri-O-acetyl-2-((S)-2-methylhex-5-ynamido)-2-deoxy- α -D-galactopyranosyl-1-phosphate (60.5 mg, 0.105 mmol). The tri-O-acetylated UDP-sugar was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on C-18 silica gel ($30\% \rightarrow 60\%$ MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). The compound was dissolved in MeOH/water/NEt₃ (5:2:1), and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM n-Bu₃NH•HCO₃; 20 mL/min; $t_r = 39.7$ min): 35.8 mg (47%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.93 (d, J = 8.1 Hz, 1H), 5.98–5.92 (m, 2H), 5.52 (dd, J =6.9, 3.4 Hz, 1H), 4.37–4.32 (m, 2H), 4.28–4.14 (m, 5H), 4.01 (d, J = 3.2 Hz, 1H), 3.94 (dd, J = 11.0, 3.2 Hz, 1H), 3.78-3.69 (m, 2H), 2.70-2.62 (m, 1H), 2.33 (t, J = 2.7 Hz)1H), 2.26–2.13 (m, 2H), 1.81–1.72 (m, 1H), 1.65–1.57 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 181.0, 167.0, 152.5, 142.3, 103.3, 95.4 (d, J = 6.5 Hz), 89.1, 85.7, 83.9 (d, J = 9.1 Hz), 74.4, 72.6, 70.3, 70.2, 69.2, 68.1, 65.6 (d, J = 5.1 Hz), 61.6, 50.2 (d, J = 8.6 Hz), 40.3, 32.7, 17.6, 16.3. ³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.6 Hz), –12.3 (d, J = 20.8 Hz). FT-IR (neat) 3252, 1674, 1540, 1463, 1430, 1393, 1350, 1235, 1115, 1078, 1058, 1036, 986, 920, 851, 814, 779, 691, 624, 511 cm⁻¹. HRMS (ESI) m/z ([M+H]⁺) calcd for C₂₂H₃₂N₃Na₂O₁₇P₂: 718.1002, found: 718.0995.



Preparation of UDP-*N*-acetyl-α-D-galactosamine derivatives (Route 2).


NHS esters were prepared according to a literature procedure.²¹ A solution of the NHS ester (0.150 mmol) in DMF (1.08 mL) was added to a mixture of UDP- α -D-galactosamine disodium salt (30.5 mg, 0.0500 mmol) in HEPES buffer (0.1 M, pH = 8.0; 1.08 mL) at 0 °C.²² The reaction mixture was allowed to warm to r.t. and stirred overnight. Next, the mixture was purified by column chromatography on C-18 silica gel (MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃). Aqueous *n*-Bu₃NH•HCO₃ solution (10 mM) was prepared by bubbling CO₂ through a solution of *n*-Bu₃NH (10 mM) in water until all *n*-Bu₃NH dissolved into the water. Fractions containing the sugar were collected, concentrated, redissolved in water (100 mL), rinsed with CH₂Cl₂ (3 x 50 mL), and concentrated. The product was purified by preparative HPLC on C-18 silica gel (MeOH/water; water was doped with 10 mM *n*-Bu₃NI+0 mM *n*-Bu₃NH•HCO₃). Pure fractions were collected, concentrated, redissolved in water (100 mL), rinsed with CH₂Cl₂ (3 x 50 mL), and concentrated. Finally, the purified compound was passed through a Bio-Rad AG[®] 50W-X8 resin (sodium form) and lyophilized.



UDP-GalNAz 2. The title compound was prepared from UDP-α-D-galactosamine ditributylammonium salt (41.7 mg, 0.0445 mmol) and 2,5-dioxopyrrolidin-1-yl 2-azidoacetate (71.0 mg, 0.358 mmol). The product was purified by column chromatography on C-18 silica gel (0%→100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 37.5 min): 10.8 mg (35%). White solid. ¹H NMR (500 MHz, D₂O) δ 7.91 (d, *J* = 8.1 Hz, 1H), 5.96 (d, *J* = 4.2 Hz, 1H), 5.93 (d, *J* = 8.0 Hz, 1H), 5.55 (dd, *J* = 7.2, 3.4 Hz, 1H), 4.37–4.31 (m, 2H), 4.31–4.05 (m, 7H), 4.02 (d, *J* = 2.6 Hz, 1H), 3.96 (dd, *J* = 10.9, 2.9 Hz, 1H), 3.79–3.69 (m, 2H). ¹³C NMR (126 MHz, D₂O) δ 171.8, 167.7, 153.0, 142.2, 103.4, 95.2 (d, *J* = 6.3 Hz), 89.3, 83.8 (d, *J* = 9.0 Hz), 74.4, 72.8, 70.3, 69.1, 68.2, 65.7 (d, *J* = 5.5 Hz), 61.7, 52.3, 50.6 (d, *J* = 8.4 Hz). ³¹P NMR (202 MHz, D₂O) δ –10.6 (d, *J* = 20.8 Hz), -12.2 (d, *J* = 20.6 Hz). FT-IR (neat) 3251, 2113, 1672, 1549, 1465, 1426, 1233, 1111, 1080, 1042, 987, 923, ⁶⁷² 0.615. ⁷ COM

853, 815, 719, 690, 623, 512 cm⁻¹.

MS (ESI) m/z ([M–2Na+H]⁻) calcd for C₁₇H₂₅N₆O₁₇P₂: 647.0751, found: 647.0738.




UDP-Sugar 7. The title compound was prepared from UDP- α -D-galactosamine disodium salt and 2,5-dioxopyrrolidin-1-yl 3-azidopropanoate. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 42.1 min). White solid.

¹H NMR (500 MHz, D₂O) δ 7.92 (d, J = 8.1 Hz, 1H), 5.97–5.92 (m, 2H), 5.53 (dd, J = 7.1, 3.5 Hz, 1H), 4.36–4.31 (m, 2H), 4.30–4.13 (m, 5H), 4.02 (d, J = 3.1 Hz, 1H), 3.94 (dd, J = 10.9, 3.1 Hz, 1H), 3.78–3.69 (m, 2H), 3.58 (t, J = 6.4 Hz, 2H), 2.69–2.58 (m, 2H).

¹³C NMR (126 MHz, D₂O) δ 175.0, 167.5, 152.9, 142.2, 103.3, 95.4 (d, *J* = 6.3 Hz), 89.2, 83.8 (d, *J* = 9.1 Hz), 74.4, 72.8, 70.3, 69.1, 68.3, 65.7 (d, *J* = 5.5 Hz), 61.7, 50.4 (d, *J* = 8.5 Hz), 47.7, 35.5.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 21.4 Hz), –12.2 (d, J = 20.6 Hz). FT-IR (neat) 3259, 2100, 1672, 1547, 1463, 1424, 1389, 1345, 1234, 1114, 1080, 1049, 985, 919, 851, 812, 767, 717, 692, 636, 620, 509 cm⁻¹.

MS (ESI) m/z ([M+H]⁺) calcd for C₁₈H₂₇N₆Na₂O₁₇P₂: 707.0703, found: 707.0706.




UDP-Sugar 9. The title compound was prepared from UDP- α -D-galactosamine disodium salt and 2,5-dioxopyrrolidin-1-yl (*S*)-3-azidobutanoate. The product was purified by preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 45.1 min). White solid.

¹H NMR (500 MHz, D₂O) δ 7.93 (d, J = 8.1 Hz, 1H), 5.97–5.92 (m, 2H), 5.53 (dd, J = 7.1, 3.5 Hz, 1H), 4.36–4.31 (m, 2H), 4.28–4.13 (m, 5H), 4.02 (d, J = 3.0 Hz, 1H), 4.00– 3.91 (m, 2H), 3.78–3.69 (m, 2H), 2.58–2.49 (m, 2H), 1.28 (d, J = 6.6 Hz, 3H). ¹³C NMR (126 MHz, D₂O) δ 174.6, 167.5, 152.9, 142.3, 103.3, 95.3 (d, J = 6.3 Hz), 89.2, 83.8 (d, J = 9.1 Hz), 74.4, 72.7, 70.3, 69.1, 68.2, 65.7 (d, J = 5.3 Hz), 61.7, 55.7, 50.4 (d, J = 8.3 Hz), 42.7, 19.3.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 21.4 Hz), –12.2 (d, J = 21.2 Hz).

FT-IR (neat) 3219, 2112, 1673, 1546, 1462, 1424, 1387, 1342, 1233, 1112, 1080, 1040, 986, 917, 852, 813, 707, 688, 620, 509 cm⁻¹. MS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0858.




UDP-Sugar 10. The title compound was prepared from UDP-α-D-galactosamine disodium salt (12.6 mg, 0.0207 mmol) and 2,5-dioxopyrrolidin-1-yl 4-azidobutanoate (14.0 mg, 0.0619 mmol). The product was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 41.3 min): 7.4 mg (50%). White solid.

¹H NMR (500 MHz, D₂O) δ 7.93 (d, J = 8.1 Hz, 1H), 5.99–5.92 (m, 2H), 5.52 (dd, J = 7.2, 3.3 Hz, 1H), 4.37–4.31 (m, 2H), 4.29–4.13 (m, 5H), 4.01 (d, J = 3.2 Hz, 1H), 3.94 (dd, J = 11.0, 2.8 Hz, 1H), 3.78–3.68 (m, 2H), 3.35 (t, J = 6.9 Hz, 2H), 2.42 (t, J = 7.5 Hz, 2H), 1.87 (p, J = 7.2 Hz, 2H).

¹³C NMR (126 MHz, D₂O) δ 177.3, 168.1, 153.3, 142.2, 103.4, 95.4 (d, *J* = 6.4 Hz), 89.2, 83.81 (d, *J* = 9.2 Hz), 74.5, 72.7, 70.3, 69.1, 68.3, 65.7 (d, *J* = 5.3 Hz), 61.7, 51.1, 50.4 (d, *J* = 8.3 Hz), 33.6, 25.2.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 21.4 Hz), –12.2 (d, J = 20.6 Hz). FT-IR (neat) 3263, 2106, 1671, 1546, 1464, 1425, 1388, 1351, 1231, 1112, 1079, 1053, 1037, 985, 918, 851, 812, 719, 688, 623, 510 cm⁻¹.

MS (ESI) m/z ([M+H]⁺) calcd for C₁₉H₂₉N₆Na₂O₁₇P₂: 721.0860, found: 721.0862.



UDP-Sugar 11. The title compound was prepared from UDP- α -D-galactosamine disodium salt (50.0 mg, 0.0821 mmol) and 2,5-dioxopyrrolidin-1-yl pent-4-ynoate (48.0 mg, 0.246 mmol). The product was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 43.5 min): 29.5 mg (52%). White solid.


¹H NMR (500 MHz, D₂O) δ 7.95 (d, J = 8.1 Hz, 1H), 5.99–5.93 (m, 2H), 5.53 (dd, J = 7.1, 3.4 Hz, 1H), 4.37–4.32 (m, 2H), 4.30–4.14 (m, 5H), 4.02 (d, J = 3.1 Hz, 1H), 3.95 (dd, J = 11.0, 3.0 Hz, 1H), 3.79–3.69 (m, 2H), 2.63–2.51 (m, 2H), 2.51–2.45 (m, 2H), 2.34 (t, J = 2.3 Hz, 1H).

¹³C NMR (126 MHz, D₂O) δ 176.0, 167.0, 152.5, 142.3, 103.3, 95.5 (d, *J* = 6.5 Hz), 89.2, 84.3, 83.8 (d, *J* = 9.1 Hz), 74.4, 72.7, 70.6, 70.3, 69.1, 68.2, 65.6 (d, *J* = 5.3 Hz), 61.7, 50.4 (d, *J* = 8.7 Hz), 35.0, 15.0.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 20.8 Hz), –12.3 (d, J = 20.6 Hz).

FT-IR (neat) 3268, 1671, 1547, 1469, 1423, 1391, 1234, 1113, 1080, 1045, 986, 919, 852, 814, 765, 712, 687, 626, 552, 514 cm⁻¹.

MS (ESI) m/z ([M+H]⁺) calcd for C₂₀H₂₈N₃Na₂O₁₇P₂: 690.0689, found: 690.0677.



UDP-Sugar 13. The title compound was prepared from UDP-α-D-galactosamine disodium salt (50.0 mg, 0.0821 mmol) and 2,5-dioxopyrrolidin-1-yl hex-5-ynoate (51.4 mg, 0.246 mmol). The product was purified by column chromatography on C-18 silica gel (0% \rightarrow 100% MeOH/water; water was doped with 10 mM *n*-Bu₃NH•HCO₃) and then preparative HPLC on an Agilent prep 100 Å C18 column (MeOH/water (min:%): 0:10, 10:10, 60:60; water was doped with 10 mM *n*-Bu₃NH•HCO₃; 20 mL/min; t_r = 38.2 min): 25.2 mg (44%). White solid.

¹H NMR (500 MHz, D₂O) δ 7.94 (dd, J = 8.2, 1.4 Hz, 1H), 5.98–5.92 (m, 2H), 5.52 (dd, J = 7.2, 3.4 Hz, 1H), 4.37–4.31 (m, 2H), 4.29–4.13 (m, 5H), 4.02 (d, J = 3.1 Hz, 1H), 3.94 (dd, J = 10.8, 2.2 Hz, 1H), 3.79–3.68 (m, 2H), 2.44 (t, J = 7.4 Hz, 2H), 2.34 (t, J = 2.6 Hz, 1H), 2.26–2.21 (m, 2H), 1.80 (p, J = 7.4 Hz, 2H).

¹³C NMR (126 MHz, D₂O) δ 177.6, 167.0, 152.5, 142.3, 103.3, 95.4 (d, *J* = 6.5 Hz), 89.1, 85.6, 83.8 (d, *J* = 9.3 Hz), 74.4, 72.7, 70.4, 70.3, 69.1, 68.3, 65.6 (d, *J* = 5.3 Hz), 61.7, 50.3 (d, *J* = 8.6 Hz), 35.3, 24.9, 17.8.

³¹P NMR (202 MHz, D₂O) δ –10.6 (d, J = 21.4 Hz), –12.2 (d, J = 20.6 Hz). FT-IR (neat) 3274, 1676, 1547, 1467, 1425, 1392, 1345, 1234, 1113, 1080, 1054, 1042, 986, 919, 852, 813, 768, 715, 687, 652, 627, 512 cm⁻¹.


MS (ESI) m/z ([M+H]⁺) calcd for C₂₁H₃₀N₃Na₂O₁₇P₂: 704.0846, found: 704.0836.


X. References


 Kubota, T.; Shiba, T.; Sugioka, S.; Furukawa, S.; Sawaki, H.; Kato, R.; Wakatsuki, S.; Narimatsu, H. Structural Basis of Carbohydrate Transfer Activity by Human UDP-GalNAc: Polypeptide α-*N*-Acetylgalactosaminyltransferase (pp-GalNAc-T10). *J. Mol. Biol.* **2006**, *359* (3), 708–727.


- (2) Lira-Navarrete, E.; Iglesias-Fernández, J.; Zandberg, W. F.; Compañón, I.; Kong, Y.; Corzana, F.; Pinto, B. M.; Clausen, H.; Peregrina, J. M.; Vocadlo, D. J.; Rovira, C.; Hurtado-Guerrero, R. Substrate-Guided Front-Face Reaction Revealed by Combined Structural Snapshots and Metadynamics for the Polypeptide N-Acetylgalactosaminyltransferase 2. *Angew. Chem., Int. Ed.* **2014**, *53* (31), 8206–8210.
- (3) Chojnacki, S.; Cowley, A.; Lee, J.; Foix, A.; Lopez, R. Programmatic Access to Bioinformatics Tools from EMBL-EBI Update: 2017. *Nucleic Acids Res.* 2017, 45 (W1), W550–W553.
- (4) Bennett, E. P.; Mandel, U.; Clausen, H.; Gerken, T. A.; Fritz, T. A.; Tabak, L. A. Control of Mucin-Type O-Glycosylation: A Classification of the Polypeptide GalNAc-Transferase Gene Family. *Glycobiology* **2012**, *22* (6), 736–756.
- (5) Guo, H.; Zhao, L.; Shi, B.; Bao, J.; Zheng, D.; Zhou, B.; Shi, J. GALNT5 uaRNA Promotes Gastric Cancer Progression through Its Interaction with HSP90. *Oncogene* 2018, *37* (33), 4505–4517.
- (6) White, T.; Bennett, E. P.; Takio, K.; Sørensen, T.; Bonding, N.; Clausen, H. Purification and cDNA Cloning of a Human UDP-*N*-Acetyl-α-D-Galactosamine:Polypeptide *N*-Acetylgalactosaminyltransferase. *J. Biol. Chem.* 1995, *270* (41), 24156–24165.
- (7) Wandall, H. H.; Hassan, H.; Mirgorodskaya, E.; Kristensen, A. K.; Roepstorff, P.; Bennett, E. P.; Nielsen, P. A.; Hollingsworth, M. A.; Burchell, J.; Taylor-Papadimitriou, J.; Clausen, H. Substrate Specificities of Three Members of the Human UDP-*N*-Acetyl-α-D-Galactosamine:Polypeptide *N*-Acetylgalactosaminyltransferase Family, GalNAc-T1, -T2, and -T3. *J. Biol. Chem.* **1997**, *272* (38), 23503–23514.
- (8) Homa, F. L.; Hollander, T.; Lehman, D. J.; Thomsen, D. R.; Elhammer, A. P. Isolation and Expression of a cDNA Clone Encoding a Bovine UDP-GalNAc:Polypeptide *N*-Acetylgalactosaminyltransferase. *J. Biol. Chem.* 1993, 268 (17), 12609–12616.
- (9) Cheng, L.; Tachibana, K.; Zhang, Y.; Guo, J.; Tachibana, K. K.; Kameyama, A.; Wang, H.; Hiruma, T.; Iwasaki, H.; Togayachi, A.; Kudo, T.; Narimatsu, H. Characterization of a Novel Human UDP-GalNAc Transferase, pp-GalNAc-T10. *FEBS Lett.* 2002, *531* (2), 115–121.
- (10) Zheng, L.; Baumann, U.; Reymon, J.-L. An Efficient One-Step Site-Directed and Site-Saturation Mutagenesis Protocol. *Nucleic Acids Res.* **2004**, *32* (14), e115.
- (11) Sibbersen, C.; Palmfeldt, J.; Hansen, J.; Gregersen, N.; Jørgensen, K. A.; Johannsen, M. Development of a Chemical Probe for Identifying Protein Targets of α-Oxoaldehydes. *Chem. Commun.* **2013**, *49* (38), 4012–4014.
- (12) Pettigrew, J. D.; Freeman, R. P.; Wilson, P. D. Total Synthesis of (-)-Xyloketal D and Its Enantiomer—Confirmation of Absolute Stereochemistry. *Can. J. Chem.* 2005, *82* (11), 1640–1648.
- (13) Smith, S. M.; Takacs, J. M. Amide-Directed Catalytic Asymmetric Hydroboration of Trisubstituted Alkenes. J. Am. Chem. Soc. **2010**, 132 (6), 1740–1741.
- (14) Studte, C.; Breit, B. Zinc-Catalyzed Enantiospecific sp³-sp³ Cross-Coupling of α-Hydroxy Ester Triflates with Grignard Reagents. *Angew. Chem., Int. Ed.* 2008, 47 (29), 5451–5455.


- (15) Agarwal, K.; Kaul, R.; Garg, M.; Shajahan, A.; Jha, S. K.; Sampathkumar, S.-G. Inhibition of Mucin-Type O-Glycosylation through Metabolic Processing and Incorporation of *N*-Thioglycolyl-D-Galactosamine Peracetate (Ac₅GalNTGc). *J. Am. Chem. Soc.* **2013**, *135* (38), 14189–14197.
- (16) Lundquist, J. T., IV; Pelletier, J. C. Improved Solid-Phase Peptide Synthesis Method Utilizing α-Azide-Protected Amino Acids. Org. Lett. 2001, 3 (5), 781– 783.
- (17) Rej, R.; Nguyen, D.; Go, B.; Fortin, S.; Lavallée, J.-F. Total Synthesis of Cryptophycins and Their 16-(3-Phenylacryloyl) Derivatives. J. Org. Chem. 1996, 61 (18), 6289–6295.
- (18) Andersen, S. M.; Heuckendorff, M.; Jensen, H. H. 3-(Dimethylamino)-1-Propylamine: A Cheap and Versatile Reagent for Removal of Byproducts in Carbohydrate Chemistry. *Org. Lett.* **2015**, 17 (4), 944–947.
- (19) Beahm, B. J.; Dehnert, K. W.; Derr, N. L.; Kuhn, J.; Eberhart, J. K.; Spillmann, D.; Amacher, S. L.; Bertozzi, C. R. A Visualizable Chain-Terminating Inhibitor of Glycosaminoglycan Biosynthesis in Developing Zebrafish. *Angew. Chem., Int. Ed.* 2014, *53* (13), 3347–3352.
- (20) Tsukamoto, H.; Kahne, D. *N*-Methylimidazolium Chloride-Catalyzed Pyrophosphate Formation: Application to the Synthesis of Lipid I and NDP-Sugar Donors. *Bioorg. Med. Chem. Lett.* **2011**, *21* (17), 5050–5053.
- (21) Zhang, Z.; Hejesen, C.; Kjelstrup, M. B.; Birkedal, V.; Gothelf, K. V. A DNA-Mediated Homogeneous Binding Assay for Proteins and Small Molecules. J. Am. Chem. Soc. 2014, 136 (31), 11115–11120.
- (22) Masuko, S.; Bera, S.; Green, D. E.; Weïwer, M.; Liu, J.; DeAngelis, P. L.; Linhardt, R. J. Chemoenzymatic Synthesis of Uridine Diphosphate-GlcNAc and Uridine Diphosphate-GalNAc Analogs for the Preparation of Unnatural Glycosaminoglycans. J. Org. Chem. 2012, 77 (3), 1449–1456.


















































































































































































































































































































































S-195

